 
 
Approval Date :  
 20-Dec-[ADDRESS_85725]-T-01-01 v3.0 Title Page 
Protocol Title: An Evaluation of the 24-Hour IOP-lo wering Effect of Bimatoprost SR in 
Participants with Open-Angle Glau coma or Ocular Hypertension 
Protocol Number:  1698-304-[ADDRESS_85726]: Bimatoprost SR 
Brief Protocol Title:  24-Hour IOP-lowering Effect of Bimatoprost SR  
Study Phase: 3b 
Sponsor Name  [CONTACT_29560]:  Allergan Sales LLC, 5 Giralda Farms, 
Madison, NJ [ZIP_CODE], [LOCATION_003] 
Emergency Telephone Number:  Refer to the study contacts page 
SAE Reporting Fax Number/Email:  
Business Unit Email Phone Fax 
Allergan [EMAIL_1588] Not applicable +[PHONE_1850] 
Backup:  +[PHONE_1851] 
 
Sponsor Signatory: 
 MD 
Vice President, Therapeutic Area Head 
Ophthalmology  
Refer to the final page of this protocol fo r electronic signature [CONTACT_51472]. 
    
     
[STUDY_ID_REMOVED]

 
 
Approval Date :  
 20-Dec-[ADDRESS_85727] of Figures ..................................................................................................................................6  
1. Protocol Summary ..................................................................................................................7  
1.1. Synopsis ...................................................................................................................... 7 
1.2. Schema ........................................................................................................................ 9 
1.3. Schedule of Activities (SoA) ....................................................................................[ADDRESS_85728] (LUMIGAN) .........................................................................[ADDRESS_85729] SR .......................................................15  
2.3. Benefit/Risk Assessment ..........................................................................................[ADDRESS_85730] SR ..........................................................................................28  
[IP_ADDRESS].  Participant Preparation .............................................................28  
[IP_ADDRESS].  Study Treatment Location........................................................28  
[IP_ADDRESS].  Administration Technique .......................................................28  
[IP_ADDRESS].  Immediate Posttreatment Observation .....................................29  
6.2. Preparation/Handling/Storage/Accountability ..........................................................29      
 
 
Approval Date :  
 20-Dec-[ADDRESS_85731]-T-01-01 v3.0 6.3. Measures to Minimize Bias: Randomization and Blinding ......................................30  
6.4. Study Treatment Compliance ...................................................................................31  
6.5. Concomitant Therapy................................................................................................31  
6.5.1.  Prohibited Interventions and Washout Before the Study ..........................................................................................................31
 
6.5.2.  Permitted Treatments .................................................................................32  
6.5.3.  Rescue Medicine ........................................................................................33  
6.5.4.  Prohibited Interventions During the Study ................................................34  
6.6. Dose Modification ....................................................................................................35  
6.7. Treatment after the End of the Study ........................................................................35  
7. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal .................................................................................................35
 
7.1. Discontinuation of Study Intervention ......................................................................36  
7.2. Participant Discontinuation/W ithdrawal from the Study ..........................................[ADDRESS_85732] to Follow Up .....................................................................................................37  
8. Study Assessments and Procedures ......................................................................................38  
8.1. Efficacy Assessments ................................................................................................38  
8.2. Safety Assessments ...................................................................................................39  
8.2.1.  Physical Examinations ...............................................................................39  
8.2.2.  Vital Signs ..................................................................................................39  
8.2.3.  Pregnancy Testing ......................................................................................40  
8.2.4.  Clinical Safety Laboratory Assessments ...................................................40  
8.2.5.  Ocular Safety Assessments ........................................................................40  
[IP_ADDRESS].  Macroscopic Conjunctival Hyperemia Assessment ...............................................................................40
 
[IP_ADDRESS].  Best-corrected Visual Acuity ...................................................40  
[IP_ADDRESS].  Visual Field ..............................................................................40  
[IP_ADDRESS].  Specular Microscopy ...............................................................40  
[IP_ADDRESS].  Biomicroscopy .........................................................................41  
[IP_ADDRESS].  Gonioscopy/Angle Assessment ...............................................41  
[IP_ADDRESS].  Pachym etry ..............................................................................41  
[IP_ADDRESS].  Dilated Ophthalmoscopy .........................................................41  
[IP_ADDRESS].  Optic Disc Examination ...........................................................41  
8.3. Adverse Events and Serious Adverse Events ...........................................................41  
8.3.1.  Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event Information ..........................................42
 
8.3.2.  Method of Detecting Adverse Events and Serious Adverse Events ..........................................................................................42
 
8.3.3.  Follow Up of Adverse Events and Serious Adverse Events .........................................................................................................42
 
8.3.4.  Regulatory Reporting Requirements for Serious Adverse Events ..........................................................................................43
 
8.3.5.  Pregnancy ...................................................................................................43      
 
 
Approval Date :  
 20-Dec-[ADDRESS_85733]-T-01-01 v3.0 8.3.6.  Medication Errors ......................................................................................43  
8.4. Treatment of Overdose .............................................................................................44  
8.5. Pharmacokinetics ......................................................................................................44  
8.6. Pharmacodynamics ...................................................................................................44  
8.7. Genetics.....................................................................................................................44  
8.8. Biomarkers and Other Assessments..........................................................................44  
8.8.1.  Anterior Segment Imaging .........................................................................44  
8.9. Health Economics .....................................................................................................44  
9. Statistical Considerations .................................................................................................... ..44 
9.1. Statistical Hypotheses ...............................................................................................44  
9.2. Sample Size Determination .......................................................................................45  
9.3. Populations for Analyses ..........................................................................................45  
9.4. Statistical Analyses ...................................................................................................45  
9.4.1.  Efficacy Analyses ......................................................................................45  
[IP_ADDRESS].  Analysis Endpoints ..................................................................45  
[IP_ADDRESS].  Primary Efficacy Analyses ......................................................46  
[IP_ADDRESS].  Secondary Efficacy Analyses ..................................................46  
[IP_ADDRESS].  Other Efficacy Analyses ..........................................................46  
9.4.2.  Safety Analyses ..........................................................................................46  
[IP_ADDRESS].  Adverse Events ........................................................................46  
[IP_ADDRESS].  Vital Signs ................................................................................47  
9.5. Interim Analyses .......................................................................................................47  
10. Supporting Documentation and Oper ational Considerations ...............................................48  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations...........................................................................................................48
 
10.1.1.  Regulatory and Ethical Considerations ......................................................48  
10.1.2.  Financial Disclosure ...................................................................................48  
10.1.3.  Informed Consent Process .........................................................................49  
10.1.4.  Data Protection...........................................................................................49  
10.1.5.  Posting Clinical Study Data .......................................................................49  
10.1.6.  Data Quality Assurance .............................................................................50  
10.1.7.  Source Documents .....................................................................................50  
10.1.8.  Study and Site Closure ...............................................................................50  
10.1.9.  Publication Policy ......................................................................................51  
10.1.10.  Compliance with Protocol..........................................................................51  
10.2.  Appendix 2: Clinical Laboratory Tests .....................................................................52  
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting ...................................................54
 
Definition of AE .......................................................................................................54  
Definition of SAE .....................................................................................................55  
Recording and Follow Up of AEs and/or SAEs .......................................................56  
Reporting of SAEs ....................................................................................................58  
10.4.  Appendix 4: Abbreviations .......................................................................................59      
 
 
Approval Date :  
 20-Dec-[ADDRESS_85734]-T-01-01 v3.0 10.5.  Appendix 5: Standard Discontinuation Criteria ........................................................61  
10.6.  Appendix 6: Study Tabular Summary ......................................................................63  
10.7.  Appendix 7: Contraceptive Guidance and Collection of Pregnancy Information..............................................................................................65
 
Definitions: ...............................................................................................................65  
Contraception Guidance: ..........................................................................................65  
Pregnancy Testing: ....................................................................................................66  
Collection of Pregnancy Information: ......................................................................67  
10.8.  Appendix 8: Study Schedule Supplement.................................................................68  
10.8.1.  Screening....................................................................................................68  
10.8.2.  Baseline ......................................................................................................69  
[IP_ADDRESS].  Office Visit...............................................................................69  
[IP_ADDRESS].  Sleep Lab Visit .........................................................................70  
10.8.3.  Day 1 ..........................................................................................................71  
10.8.4.  Day 2 Safety Visit ......................................................................................72  
10.8.5.  Day 8 Phone Call .......................................................................................72  
10.8.6.  Week 8 Visits .............................................................................................72  
[IP_ADDRESS].  Office Visit...............................................................................72  
[IP_ADDRESS].  Sleep Lab Visit .........................................................................73  
10.8.7.  Week 16 and Months 6, 9, and 12/Study Exit Visits .................................74  
11. References .................................................................................................................... .........76      
 
 
Approval Date :  
 20-Dec-[ADDRESS_85735] of Tables 
Table 1-1  Schedule of Activities – Screening through Week 8 ............................................ 10  
Table 1-2  Schedule of Activities – Week 16 through Month 12/Study Exit ........................ 12  
Table 6-1  Study Treatment Administered ............................................................................. 27  
Table 6–[ADDRESS_85736] of Figures 
Figure 1-1  Study Schema.......................................................................................................... 9  
 
     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85737]-T-01-01 v3.0 1. Protocol Summary 
1.1. Synopsis 
Protocol Title: An Evaluation of the 24-Hour IOP-lo wering Effect of Bimatoprost SR in 
Participants with Open-Angle Glau coma or Ocular Hypertension 
Protocol Number:  1698-304-007 
Brief Title:  24-Hour IOP-lowering Effect of Bimatoprost SR 
Study Phase:  3b 
Study Rationale: Results of the completed 24-month Phase 1/[ADDRESS_85738] SR at dose strengths  of 20 µg (2 × 10 µg) or less (15, 10, and 6 µg) 
in the Phase 1/[ADDRESS_85739] udy with initial schedule d and subsequent “as 
needed” repeat administration(s) of Bimatoprost SR  
are ongoing. The current study (1698-304-007) is a multicenter, open-label Phase 3b study to 
evaluate the IOP-lowering effect over [ADDRESS_85740] SR treatment, with safety assessed through Month 
12. 
Objectives and Endpoints: 
Objectives Endpoints/Measures 
Efficacy: 
Primary 
 To evaluate the 24-hour IOP-lowering effect of 
Bimatoprost SR in participants with OAG or 
OHT  
 
Secondary 
 To evaluate the change in diurnal variation of 
IOP in eyes treated with Bimatoprost SR  
 
Other 
 To evaluate the IOP-lowering effect of 
Bimatoprost SR   
 Time-matched IOP change  from Baseline Sleep 
Lab visit at Week [ADDRESS_85741] 
SR-treated eyes  
 
 
 Change from baseline in range of IOP in eyes 
treated with Bimatoprost SR at Week 8 Sleep Lab 
visit  
  
 Hour 0 IOP change from baseline through 
Month 12 
 Time to initial use of nonstudy IOP-lowering treatment    

 
 
Approval Date :  
 20-Dec-[ADDRESS_85742]-T-01-01 v3.0 Objectives Endpoints/Measures 
Safety: 
 To evaluate the safety of Bimatoprost SR in participants with OAG or OHT 
  AEs, visual fields, visu al acuity, macroscopic 
bulbar conjunctival hyperemia, slit-lamp 
biomicroscopic assessments, dilated 
ophthalmoscopic assessments (including optic disc 
assessment), contact [CONTACT_78536], 
gonioscopy, specular microscopy 
 
Overall Study Design:  This is a multicenter, open-label, Phase 3b study in participants with 
OAG or OHT.  
Number of Participants:  Approximately 35 participants will be enrolled: [ADDRESS_85743] SR cohort (to achieve a minimum tota l of [ADDRESS_85744] SR, assuming a premature 
discontinuation rate of up to 33%), and 5 in the LUMIGAN® 0.01% (bimatoprost ophthalmic 
solution) cohort. Participants who prematurely discontinue from the study will not be replaced. Number of Sites: Approximately 3 sites in the [LOCATION_002]  
Intervention Group and Study Duration:   
Participants in the Bimatopros t SR cohort will receive a [ADDRESS_85745] of car e treatment (provided that there is no known 
crossover effect of the fellow ey e’s standard of care treatment to the study eye) for the duration 
of the study. At selected site(s) an additional cohort  of participants will be enrolled and assigned 
to receive topi[INVESTIGATOR_78499] 0.01% in the study ey e (once daily, at 20:00 ± 1 hour, starting with 
the evening dose on Day 1), and stan dard of care treatment in the fellow eye (provided that there 
is no known crossover effect of the fellow eye’s st andard of care treatment to the study eye) for 
the duration of the study. Participants will be  assigned to the Bimatoprost SR cohort or 
LUMIGAN 0.01% cohort by [CONTACT_093]. 
The participant and investigator will not be ma sked to the study treatment assignment for the 
duration of the study. Site staff collecting 24-hour IOP measurements at Sleep Lab visits will be 
masked to the study treatment and study eye. 
Study Eye Treatment Fellow Eye Treatment 
Bimatoprost SR 10 µg or LUMIGAN 0.01%a  
(at selected site[s]) Standard of Care  
a Participants will begin self-administration of LUMIGAN 0.01% in the study eye once daily in the evening (20:00 ± 1 hour)  
starting with the evening dose on Day 1, and will continue self-administration daily through the duration of the study. 
The duration of the study for each participant is approximately 15 months, consisting of a 
screening period of up to 60 days before was hout, washout period of up to 42 days before 
Baseline, and 12 months of follow-up. 
Data Monitoring Committee:  No    
 
 
 
 
Approval  Date:  
 20-Dec-[ADDRESS_85746]-T-01-01 v3.0  Table 1-2 Schedule of Activities – Week 16 through Month 12/Study Exit 
Visit Week 16 Month 6 Month 9 Month 12/ Study 
Exit 
Visit Windows ± 4 days ± 14 days ± 14 days ± 14 days 
Adverse Events X X X X 
Concomitant Medications/ Procedures X X X X 
Vital Signs (at rest ≥ 5 minutes) X X X X 
Pregnancy Test    X 
Ocular Examinations in bold should be performed in the order shown 
Pre-Hour 0 Exams  (perform before Hour 0 IOP):  
Macroscopic Conjunctival Hyperemia Assessment OU OU OU OU 
Best-Corrected Visual Acuity  OU OU OU OU 
Intraocular Pressure Measurement Hour 0 OU OU OU OU 
Anterior Segment Imaginga (may perform any time after Hour 0 IOP)  OU  OU 
Non-contact [CONTACT_78537]  (may perform in any order at any time be fore gonioscopy, including prior to H0 IOP)  
Visual Fieldb  OU  OU 
Manifest Refractionc    OU 
Specular Microscopyd OU OU OU OU 
Biomicroscopy OU OU OU OU 
Gonioscopy/Angle Assessment  OU OU OU OU 
Pachymetry: (may be performed any time after non-contact [CONTACT_78538]) OU OU OU OU 
Pupil Dilation   (may perform exams in any order)    OU 
Dilated Ophthalmoscopy     OU 
Optic Disc Examination    OU 
Contact [CONTACT_78539]    X 
Hour 0 = 08:00 ± 1 hour assessed with a Goldmann applanation tonometer 
a At selected sites/selected participants onl y, anterior segment imaging may be performe d in both eyes of consenting participants  using Allergan-approved instruments. 
b For a given participant, the same test methodology must be used  for all visual fields performed at Screening, Baseline, and throughout the study. 
c Manifest refraction will be used to provide  a correction for best-corrected visual acu ity testing. At all study visits, if the re is a 2-line or more reduction in visu al acuity from the last best-corrected 
visual acuity performed, a repeat manifest refraction in both eyes and best-corrected visual acuity will be performed. 
d For a given participant, the same specular microscope model and analysis methodology mu st be used at Screening, Baseline, and throughout the study. 
e       Contact [CONTACT_78540]/withdrawal.      
 
 
Approval Date :  
 20-Dec-[ADDRESS_85747] 
implant that is preloaded in an applicator fo r administration; together they comprise the 
Bimatoprost SR product. The Bimatoprost SR im plant is injected into  the AC through clear 
cornea adjacent to the corneoscleral limbus using the 28-gauge needle of th e prefilled applicator. 
The biodegradable polymer matr ix of the implant gradually degrades to carbon dioxide and 
water so that there is no need to remove th e implant once the drug has been released. The 
Bimatoprost SR implant used in this study contai ns a total preservative-free bimatoprost load of 
10 µg. Intracameral administration of the 10 µg implant is expected to reduce the total daily drug 
exposure to the eye by [CONTACT_3450] 120-fo ld compared with daily topi[INVESTIGATOR_78499]® 0.03% 
(bimatoprost ophthalmic solution) application over  4 to 6 months, as well as possibly reduce the 
adverse effects observed with topi[INVESTIGATOR_78500]. To date, 24-hour (diurnal and 
nocturnal) IOP data collection in participants ad ministered with Bimatoprost SR has not been 
performed. 
2.1. Study Rationale 
Results of the completed 24-month Phase 1/[ADDRESS_85748] SR at dose strengths of 20 µg (2 × 10 µg) or less (15, 10, and 6 µg) in the Phase 1/[ADDRESS_85749] SR at fixed 16 week intervals, 1 global 
extension study, and 1 global Phase 3b study with initial scheduled and subsequent “as needed” 
repeat administration(s) of Bima toprost SR  are all 
ongoing. The current study (1698-304-007) is a multicenter, open-label Phase 3b study to 
evaluate the IOP-lowering effect over [ADDRESS_85750] types: developmental, angle-closure, and 
open-angle glaucoma (Stamper 2009 ). Open-angle glaucom a is further categorized into primary 
OAG (POAG, sometimes also referred to as ch ronic OAG) and secondary OAG (which includes 
pi[INVESTIGATOR_78501]), w ith POAG being the predominant form of OAG. 
POAG is characterized as a multifactorial optic neuropathy with a characteristic acquired atrophy 
of the optic nerve and loss of ganglion cells and their axons, de velopi[INVESTIGATOR_78502] :  
 20-Dec-[ADDRESS_85751]-T-01-01 v3.0  AC angles, and manifesting characte ristic visual field abnormalities ( American Academy of 
Ophthalm ology 2010a, Skuta 2008).  Globally, over 60 million people are estimated to be 
affected by [CONTACT_78541] (the majority of whom have OAG) and these num bers are expected to 
increase over tim e (Quigley 2006, Varma 2011, Cook 2012 ). Approxim ately 10% of eyes with 
elevated IOP will progress to OAG over the cour se of a decade ( Quigley 1994).  
Although many risk factors have been associated with OAG, elevated IOP remains the most 
prominent factor and the only factor existing th at ophthalmic intervention can reliably affect 
(Stamper 2009 ). A num ber of controlled trials have demonstrated that lowering IOP will slow or 
delay the appearance or progressi on of glaucoma tous damage. Large,  randomized clinical trials 
such as the Ocular Hypertension Treatme nt Study ( Kass 2002 ) and the Early Man ifest Glaucoma 
Trial ( Heijl 2002 ) addressed the value of early detection and lowering of elevated IOP in ocular 
hypertension or POAG. The effects and paramete rs of various interventions in eyes with 
established glaucomatous damage were addr essed by [CONTACT_78542] ( Lichter 2001 ) and the Advanced Glaucom a Intervention Study ( AGIS 2000 ). 
2.2.2.  Bimatoprost (LUMIGAN) 
Bimatoprost is a member of a series of unique prostanoid compounds that are potent and 
efficacious ocular antihypertensi ve agents ( Woodward 1994, 2001, and 2004 ). Bim atoprost 
appears to mim ic the activity of biologi cally active prostamides (Study BIO 99 308, 
Matias 2004 ). Chem ically, prostamides differ from prostaglandin analogs by [CONTACT_78543] ( Krauss 2004 ). Prostamides can be biosynthetically derived 
from anandam ide, an endogenous membrane lipid ( Kozak 2002, Weber 2004, Woodward 2001, 
Yu 1997). The prostam ide pathway leads to the bi osynthesis of novel lipid amides that lower 
IOP. 
The IOP-lowering efficacy of LUMIGAN 0.03% is well established. In Phase 3 studies in 
patients with POAG or OHT, LUMIGAN administer ed once daily as monotherapy was superior 
to timolol at all timepoints through 12 m onths ( Higginbotham 2002 ). This was further 
substantiated in the extension studie s which fo llowed patients in a masked manner for up to 4 
years ( Cohen 2004, Williams 2008 , Study 192024-014). In clinical st udies of patients with OAG 
or OHT with a mean baseline IOP of [ADDRESS_85752] of LUMIGAN 
administered once daily in the ev ening was 7 to 8 mm Hg (Cohen 2004,  LUMIGAN Package 
Insert 2017, Williams 2008). LUMIGAN 0.03% was approved by [CONTACT_40563] 2001. 
Worldwide, LUMIGAN 0.03% is currently licensed and marketed in more than 80 countries and 
LUMIGAN 0.01% is licensed and marketed in more than [ADDRESS_85753] ophthalmic solution 0.03% has b een approved since November 2012 for lowering 
IOP and is currently marketed in 10 countries. 
2.2.3.  Other Biodegradable Ocular Implants 
Formulation of a number of SR drug delivery implants using the Allergan PLA and/or PLGA 
biodegradable platform preceded the development of the Bimatoprost SR implant. The extensive 
clinical experience with the OZURDEX® implant (first approved in 2009 and is registered 
globally in over 70 countries),  which also uses the NOVADUR® drug delivery system for     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85754] SR 
Study 192024-041D was a Phase 1/[ADDRESS_85755] SR (6, 10, 15, or 20 µg [2 x10 µg implants]), as 
single or repeat administrations in 1 eye (st udy eye), versus the use of topi[INVESTIGATOR_78499] 0.03% 
once daily in the contralateral eye (nonstudy eye). The objective of the study was to evaluate the 
safety and IOP-lowering efficacy of Bima toprost SR in participants with OAG.  
A total of [ADDRESS_85756] SR implant: the original Generation [ADDRESS_85757] part icipants (> 66%) were still maintained on 
monotherapy with the initial Bi matoprost SR implant by [CONTACT_43380] 6.  Additionally, at least 33% of 
participants had not re ceived rescue topi[INVESTIGATOR_15434]-lowering medication or a second Bimatoprost 
SR administration by [CONTACT_43380] 12. At Month 24, at  least 23% of particip ants had not received 
rescue IOP-lowering  treatment or a s econd administration of Bimatoprost SR. 
Bimatoprost SR showed an acceptable safety profile  with single and repeat administrations in 
Study 192024-041D. Most AEs were ocular, mild or m oderate in severity, occurred within the 
first [ADDRESS_85758] SR. Please re fer to the investigator’s  brochure for details on 
reported safety findings. 
The implant is being investigated in Phase 3 stud ies to evaluate efficacy and safety following a 
fixed administration schedule of every 16 week s for up to 3 administrations. Two identical 
global Phase 3 studies (Studies 192024-091 [[STUDY_ID_REMOVED]] and 192024-092 [[STUDY_ID_REMOVED]]) 
were initiated in late 2014. These studies are assessing the safety and efficacy of Bimatoprost SR 
in multicenter, randomized, masked, parallel -group comparisons of [ADDRESS_85759] SR (10 and 15 µg) to an active control (topi[INVESTIGATOR_78503] 0.5%). 
Two additional global Phase 3 studies (Studies 192024-093 [[STUDY_ID_REMOVED]] and 192024-095 [[STUDY_ID_REMOVED]]) were initiated in late 2015. These studies are assessing the safety and efficacy     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85760] SR (10 µg or 15 µg) to an active control (360° SLT).  Participants from 
all [ADDRESS_85761] the opportunity to  participate in a long-term safety and efficacy 
extension study (Study 1698-302-007 [[STUDY_ID_REMOVED]]), with potential repeat “as needed” 
administration(s) of Bimatoprost SR 10 or 15 µg if they qualify; this extension study was 
initiated in early 2019. Additionally, the implant is  also being investigat ed in a global Phase 3b 
study (1698-301-007 [[STUDY_ID_REMOVED]]) initiated in early [ADDRESS_85762] 
and safety of up to 3 “as needed” administrations of Bimatoprost SR.   
2.3. Benefit/Risk Assessment 
Although a variety of effective topi[INVESTIGATOR_78504] (including 
bimatoprost) are available, pati ent nonadherence to topi[INVESTIGATOR_52201] y is one of the major challenges 
to preventing vision loss due to glaucoma, as consistent IOP  reduction is associated with reduc ed 
risks of the development and progr ession of optic nerve dama ge (Friedman 2009, Tsai 2009). 
One literature review found that up to 80% of patients deviated fr om their prescribed medication 
regimen ( Olthoff 2005 ). In addition, most patients with OAG or OHT are elderly, and many have 
inherent difficulties applying da ily antihypertensive eye drops due  to physical and/or cognitive 
disabilities such as arthritis and poor memory (European Glaucoma Society Guidelines 2014, 
Tsai 2009) . Guidelines for clinic ians to assist patien ts with being adherent have been developed 
and are av ailable (Budenz 2009 ). In a ddition, surgical interventions, both laser-based (eg, LT) 
and incisional, are recommended as treatment options for patients with OAG and OHT who have 
challenges with topi[INVESTIGATOR_78505] (European Glaucoma Society 
Guidelines 2014). Laser trabeculoplasty is a safe and noninvasive procedure; however, 
repeatability of LT is inconsistent  (Realini 2008 ). Repeat ALT procedures are lim ited due to 
tissue fibrosis and scarring of the trabecular meshwork ( Kramer 2001 ). While the SLT procedure 
is repeatable, mean IOP reductions followi ng repeat SLT appears to be smaller ( Garg 2018). 
Patients will often require adjunctive therapy af ter LT, and m ay eventually require incisional 
surgery to control their IO P (Francis 2005, Koucheki 2012).  Incis ional surgery presents the risk 
of significant sight-threatening complications, such as the globe perforation, suprachoroidal 
hemorrhage, hypotony maculopathy, corneal d ecompensation, and cataract for mation or 
progression that ma y occur with filtering surgery ( Mosaed 2009 ). Allergan has developed the 
Bimatoprost SR implant as an additional therapeutic option for lowering IOP in patients with OAG and OHT. 
IOP is a dynamic parameter that has circadian and postura l variations, with IOP typic ally 
elevated at night when an indivi dual is in a supi[INVESTIGATOR_2547] ( Liu 1999). The m agnitude and 
timing of peak IOP values m ay be an inde pendent contributor to glaucoma progression 
(Konstas 2012 ). Due to the fluctuating nature of  IOP, affected by [CONTACT_78544], uniform reduction throughout  a 24 hour period is a desired therapeutic 
target ( Liu 2005). Patients typi[INVESTIGATOR_78506]’s office during the day, which are usually 
limited to typi[INVESTIGATOR_2855] “business hours. ” Measuring a single IOP value at  a single timepoint in this 
limited window may fail to capture the breadth of varia tion of an individual’s IOP over the full 
24 hours in a day. For patients with OAG and/ or OHT, Bimatoprost SR offers ocular 
antihypertensive therapy that is not dependent on daily patient se lf-administration, potentially     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85763]-T-01-01 v3.0  improving both treatment adherence and continu ous IOP control. Based on data from a 
completed Phase 1/[ADDRESS_85764] SR, may be found in the investigator’s brochure.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85765]-T-01-01 v3.0  3. Objectives and Endpoints 
Objectives Endpoints/Measures 
Efficacy: 
Primary 
 To evaluate the 24-hour IOP-lowering effect of 
Bimatoprost SR in participants with OAG or OHT  
 
Secondary 
 To evaluate the change in diurnal variation of 
IOP in eyes treated with Bimatoprost SR  
 
Other 
 To evaluate the IOP-lowering effect of 
Bimatoprost SR   
 Time-matched IOP change  from Baseline Sleep 
Lab visit at Week [ADDRESS_85766] SR-treated eyes 
 
 
 Change from baseline in range of IOP in eyes 
treated with Bimatoprost SR at Week 8 Sleep Lab 
visit 
 
 
 Hour 0 IOP change from baseline through 
Month 12 
 Time to initial use of nonstudy IOP-lowering treatment 
Safety: 
 To evaluate the safety of Bimatoprost SR in 
participants with OAG or OHT 
  AEs, visual fields, visu al acuity, macroscopic 
bulbar conjunctival hyperemia, slit-lamp 
biomicroscopic assessments, dilated 
ophthalmoscopic assessments (including optic disc 
assessment), contact [CONTACT_78536], gonioscopy, specular microscopy 
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85767]-T-01-01 v3.0  4. Study Design 
4.1. Overall Design 
This is a multicenter, open -label, Phase 3b study in pa rticipants with OAG or OHT. 
Approximately 35 participants will be enrolled : [ADDRESS_85768] SR cohort (to 
achieve a minimum total of [ADDRESS_85769] SR, assuming a premature discontinuation rate of up 
to 33%), and 5 in the LUMIGAN 0.01% cohort. Pa rticipants who prematurely discontinue from 
the study will not be replaced. 
Participants in the Bimatopros t SR cohort will receive a [ADDRESS_85770] of car e treatment (provided that there is no known 
crossover effect of the fellow ey e’s standard of care treatm ent to the study eye) for the duration 
of the study (see Sections 6.5.2 and 6.5.4 f or additional details). At se lected site(s) an additional 
cohort of participants will be enrolled and a ssigned to receive topi[INVESTIGATOR_78499] 0.01% in the 
study eye (once daily, at 20:00 ± 1 hour, starting with the evening dose on Day 1), and standard 
of care treatment in the fellow ey e (provided that there is no know n crossover effect of the fellow 
eye’s standard of care treatment to the study eye) for the duration of the study. Participants will 
be assigned to the Bimatoprost SR cohort or  LUMIGAN 0.01% cohort .  
The participant and investigator will not be ma sked to the study treatment assignment for the 
duration of the study. Site staff collecting 24-hour IOP measurements at Sleep Lab visits will be 
masked to the study treatment and study eye. 
Study Eye Treatment Fellow Eye Treatment 
Bimatoprost SR 10 µg or LUMIGAN 0.01%a  
(at selected site[s]) Standard of Care  
a Participants will begin self-administration of LUMIGAN 0.01% in the study eye once daily in the evening (20:00 ± 1 hour)  
starting with the evening dose on Day 1, and will continue self-administration daily through the duration of the study. 
The duration of the study for each participant is approximately 15 months, consisting of a 
screening period of up to 60 days before washout; washout period of up to 42 days before 
Baseline; and [ADDRESS_85771] inform ation on the 24-hour (diurnal and nocturnal) IOP 
profile after a single administ ration of Bimatoprost SR.  
4.3. Justification for Dose 
The [ADDRESS_85772] SR is 1 of 2 dose strengths currently being evaluated in 
ongoing Phase 3 studies. Based on data from the completed Phase 1/2 Study 192024-041D, the    

 
 
Approval Date :  
 20-Dec-[ADDRESS_85773] completed the study if he/she has completed all visits of th e study to Month 12. At the Month 12/Study Exit 
visit, if the investigator determines that any safety concerns warrant participant follow-up, the 
participant may be followed post exit until safety concerns are resolved based on the 
investigator’s discretion. Part icipants assigned and treated with LUMIGAN 0.01% may early 
exit the study after completion of th e Week 8 Sleep Lab visit, if there are no safety concerns in 
the opi[INVESTIGATOR_871], and at whic h time all assessments performed at the 
Month 12/Study Exit visit should be performed.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85774] 1 eye that requires 
IOP lowering treatment and has an open iridocorneal angle inferiorly by [CONTACT_78545]. The 
eye that meets the entry criteria (Sections 5.1 an d 5.2) will be selected as the study eye. If both 
eyes meet the entry criteria, the eye with the hi gher IOP at Baseline Hour [ADDRESS_85775] the same IOP, then the right eye will be designated as the study 
eye.   
Prospective approval of protocol deviations to recruitment and en rollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
1. Age 
1.[ADDRESS_85776] 18 years of  age at the time of signing the informed 
consent  
2. Sex 
2.01 Male or female  
3. Informed Consent  
3.01 Written informed consent and authorization for use and release of personal health 
information are obtained in accordance with the relevant country and local privacy 
requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection 
consent [EU sites])
 
4. Contraceptives  
4.01 Female participants willing to minimize the risk of inducing pregnancy for the 
duration of the clinical study and follow-up period  
4.02 A female participant is eligible to par ticipate if she is not p regnant (ie, has a negative 
urine pregnancy result at Baseline; see Appendix 7), not breastfeeding, and at least 1 
of the following conditions applies: 
a. Not a WOCBP as defined in Appendix 7 
OR 
b. A WOCBP who agrees to follow the c ontraceptive guidance in Appendix 7 
during the study period    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85777]-T-01-01 v3.0  5. Other General Criteria  
5.01 Participant is willing to withhold his/her IO P treatments in both eyes according to 
the study requirements, and in the opi[INVESTIGATOR_871], can do so without 
significant risk 
Note: If participants cannot discontinue their currently prescribed therapy in both 
eyes for up to 6 weeks to meet the Washout  period for study entry, the investigator 
may switch the participant’s medication to  one that requires  a shorter washout 
interval during the washout of the original medication.   
5.02 Participant has the ability to understand and willingness to  follow study instructions 
and is likely to complete a ll required visits and procedures   
5.03 Participant is currently a nonsmoker and has not smoked any nicotine-containing 
products within the previous 6 months  
6. Ocular Inclusion Criteria 
6.01 Diagnosis of either OAG (ie, primary OAG, pseudoexfoliation glaucoma, pi[INVESTIGATOR_11232]) or OHT in the  study eye , requiring IOP-lowering treatment
 
6.02 In the investigator’s opi[INVESTIGATOR_1649],  the study eye could be treated adequately with topi[INVESTIGATOR_78507], prostaglandin, or prostagl andin analog (eg, LUMIGAN, Xalatan, 
Travatan) eye drops as the sole therapy  
6.[ADDRESS_85778] SR implant using the following criteria: 
a. Shaffer Grade ≥ 3 on clinical gonioscopy of the inferior angle 
b. Peripheral anterior chamber depth by [CONTACT_78546] ≥ 1/2 corneal 
thickness 
6.04 At the Baseline visit, participant has been appropriately washed out of all 
IOP-lowering medications  
6.05 At the Baseline visit (08:00 ± 1 hour), IOP of ≥ 22 and ≤  34 mm Hg in the study eye 
using a Goldmann applanation tonometer  
6.06 Central corneal endothelial cell density by [CONTACT_78547], 
in the opi[INVESTIGATOR_67472] (at Screening, an d a minimum endothelial cell 
density of 1800 cells/mm2 in the study eye  by [CONTACT_78548])  
6.07 At the Baseline visit: best -corrected visual acuity (Sne llen equivalent, by [CONTACT_78549]) of 20/50 or better in the study eye  and 20/100 or better in the fellow eye  
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85779]-T-01-01 v3.0  2.04 The following surgical history in the study eye : 
a. History or evidence of comp licated cataract/lens surgery: eg, surgery resulting in 
complicated lens placement (such as anteri or chamber IOL, sulcus IOL, aphakia, 
etc.) or intraoperative comp lications (such as a posterio r capsular tear [with or 
without vitreous loss], substa ntial iris trauma, etc.)  
Note: history of uncomplicated cataract surgery is not an exclusion 
b. History of phakic IOL insertion for refractive error correction 
2.05 Intraocular surgery (including cataract surgery) in the study eye  within the [ADDRESS_85780] SR administration  
2.06 Any history of corneal graft,  including partial grafts (eg, Descemet’s Strippi[INVESTIGATOR_78508] [DSEK], Descemet’s Membrane Endothelial Keratoplasty 
[DMEK]); or incisional refractive surgery (eg, radial keratotomy), other than astigmatic 
keratotomy or limbal relaxing incisions in the study eye 
2.07 Corneal or other ocular abnormalities that would preclude accurate readings with an 
applanation tonometer, specular microscope, and/or a contact [CONTACT_78550], or could 
confound study results in either eye , eg, moderate to severe corneal dystrophy, including 
Anterior Basement Membrane Disease (ABM D; ie, Map-Dot-Fingerprint) and guttata. 
Mild ABMD or mild guttata are not exclusionary by [CONTACT_78551], in the opi[INVESTIGATOR_871], the condition is stable and not li kely to cause corneal changes 
during the course of the study
 
2.08 Active or recurrent ocular disease in the study eye  (eg, uveitis, ocular  infection, chronic 
moderate to severe blepharitis or severe dr y eye, ocular seasonal allergies) or sight 
threatening diseases (eg, neovascular age-re lated macular degeneration [AMD], diabetic 
macular edema) that, in the opi[INVESTIGATOR_2511] i nvestigator, would put the participant at a 
significant risk or would interfere with the interp retation of the study data 
Note: Participants with slowly progressi ve eye diseases (ie, mild cataracts, 
non-neovascular AMD) can be enrolled at th e discretion of the investigator. If a 
participant has a potentially exclusionary condit ion or disease in one eye that tends to be 
bilateral or is likely to affect both eyes, th e investigator should consider excluding that 
participant  
2.09 Any history of external ocular or intraocu lar malignancy, and/or any history of benign 
ocular neoplasia in the study eye  that in the investigator’s opi[INVESTIGATOR_78509]  
2.10 History of herpetic ocular diseases in the study eye  (including herpes simplex virus and 
varicella zoster virus)  
2.11 Active ocular surface findings other than  bulbar conjunctival hyperemia, on either 
macroscopic or slit-lamp examination, > +1 (mild) at Baseline in the study eye     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85781] lenses in the study eye during the study that deviates 
from the following (contact [CONTACT_78552], but is to be 
temporarily discontinued before study visi ts, and before and after Bimatoprost SR 
administration according to the following): 
a. Use of soft lenses should be discontinued at  least [ADDRESS_85782] lenses of any kind from  08:00 ± [ADDRESS_85783] IOP measurement of Sleep Lab vi sits ending at 06:00 ± 30 minutes 
2.13 Central corneal thickness of < 480 or > 620 micrometers in the study eye  
2.14 Anticipated need for any incisional or laser ocular surgery in the study eye  during the 
study  
2.15 History of anatomically narrow angle resulting in evidence of angle changes, and/or any 
history of acute angle cl osure glaucoma, in the study eye  
Note: historically narrow-angled participants  who have not experienced an acute attack 
of angle closure and whose angle has been  opened by [CONTACT_78553]  
2.16 History or evidence of a peri pheral iridotomy/iridectomy in the inferior iris in the study 
eye 
2.17 Any history of trabeculectomy or other types of glaucoma surgery, including a glaucoma 
seton or aqueous by[CONTACT_78554]  (including MIGS) in the study eye  
2.18 Any history of intracameral implants or intracameral device administration in the study 
eye 
2.19 Peripheral anterior synechiae in the in ferior iridocorneal angle on gonioscopic 
examination at Screening in the study eye  
2.20 Visual field loss in either eye  that, in the opi[INVESTIGATOR_871], is functionally 
significant (eg, split fixation, fi eld defect within the central 10 degrees that is visually 
significant or likely to cause central visu al impairment upon progression) or shows 
evidence of progressive visual field loss within the year prior to Baseline  
Note: The same test methodology should be us ed for all study-related examinations for a 
given participant  
2.21 Evidence of macular edema in either eye  during screening or in participant’s medical    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85784]-T-01-01 v3.0  history 
2.22 Anticipated use of corticosteroids in either eye  (except as described in Section 6.5.2 ) or 
systemically during the study, or histor ical use prior to Baseline within: 
a. 3 years: intraocular fluocinolone acetonide 
b. 6 months: intraocular corticosteroid(s) other than fluocinolone; any injectable 
periocular or sub-Tenon’s/subc onjunctival corticosteroid 
c. 2 months: systemic (eg, oral, intramuscular, intrav enous) or topi[INVESTIGATOR_78510]  
d. 2 weeks: dermal corticosteroids applied to skin of the eyelid(s), around the eye, or 
adnexa 
2.23 Anticipated use of other topi[INVESTIGATOR_78511] 6.5.2. 
 
5.3. Lifestyle Considerations 
5.3.1.  Caffeine, Alcohol, Tobacco, and Sleep 
1. Though not required, participants should be  encouraged to maintain a consistent 
8-hour sleep schedule for 7 da ys prior to Sleep Lab visits. Participants’ sleep 
schedules in the 7 days prior to each Sleep Lab will be recorded at the 
corresponding Sleep Lab visit. 
2. Though not required, participants should be encouraged to abstain from ingesting caffeine- or xanthine-containing products  (eg, coffee, tea, cola drinks, and 
chocolate) for [ADDRESS_85785] IOP measurement of Sleep Lab visit 
beginning at 08:00 ± 30 min. From 08:00 ± [ADDRESS_85786] 
IOP measurement of Sleep Lab visit endi ng at 06:00 ± [ADDRESS_85787] IOP measurement of Sleep Lab visit beginning 
at 08:00 ± 30 minutes. From 08:00 ± [ADDRESS_85788] IOP 
measurement of Sleep Lab visit ending at  06:00 ± [ADDRESS_85789] not smoked any 
nicotine-containing products within the previous 6 months. 
5.4. Screen Failures 
Screen failures are defined as participants who c onsent to participate in the clinical study but are 
not subsequently entered in the study. A minimal set of screen failure information is required to    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85790]-T-01-01 v3.0  ensure transparent reporting of screen failure participants to meet the CONSORT publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
includes indicating screen failure as reason for ending the study, demography, screen failure 
details, eligibility criteria, and any SAE. 
Individuals who do not meet the cr iteria for participation in this  study (screen failures) may not 
be rescreened unless the particip ant’s condition has changed, in the investigato r’s opi[INVESTIGATOR_1649].  
6. Study Treatment 
Study intervention is defined as any investigational interven tion(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the 
study protocol. 
6.1. Study Treatment Administered 
Details regarding the study treatment administered is summ arized in Table 6-[ADDRESS_85791] SR At Selected Site(s) 
LUMIGAN 0.01% (Bimatoprost 
Ophthalmic Solution) 
Dosage Formulation Bimatoprost SR is an intraocular implant that 
contains preservative-free bimatoprost dispersed in a biodegradable polymer matrix 
(including PLA and/or PLGA). Implants are 
preloaded into an applicator to facilitate 
insertion of the implant into the AC of the 
eye. LUMIGAN 0.01% contains bimatoprost 0.01%, benzalkonium chloride, sodium chloride, sodium 
phosphate, dibasic, citric acid, and 
purified water. 
Unit Dose Strength/ 
Dosage Level A dose strength of 10 µg (formula number 
11047X) bimatoprost will be administered. A dose strength of 0.01% bimatoprost 
ophthalmic solution will be administered. 
Route of Administration  Intracameral Topi[INVESTIGATOR_78512]. LUMIGAN 0.01% is instilled 
topi[INVESTIGATOR_78513] (20:00 ± 1 hour). 
Packaging and 
Labeling Study treatment will be provided in a sterile, 
laminated foil pouch in an individual carton. 
Each package will be labeled as required per country requirement.
 Licensed and approved LUMIGAN 
0.01% will be acquired by [CONTACT_16547] a 
multidose bottle. 
Manufacturer Allergan Allergan    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85792] SR At Selected Site(s) 
LUMIGAN 0.01% (Bimatoprost 
Ophthalmic Solution) 
Number and Timing of Treatments This study consists of [ADDRESS_85793] SR administration in the study eye: 
 On Day 1, participants will receive an 
intracameral administration of Bimatoprost 
SR [ADDRESS_85794] 
of care treatment in the fellow eye (provided 
that there is no known potential crossover 
effect of the fellow eye’s standard of care 
treatment to the study eye).  On Day 1, the participant will begin treatment with LUMIGAN 0.01%. 
The drop will be instilled once daily 
in the evening (20:00 ± 1 hour) to the 
study eye throughout the duration of 
the study. Standard  of care treatment 
will be used in the fellow eye 
(provided that there is no known 
potential crossover effect of the fellow eye’s standard of care 
treatment to the study eye).  
 
6.1.1.  Instructions for Use and Admini stration of Bimatoprost SR 
Study treatment must only be administered to part icipants who meet the e ligibility criteria in 
accordance with conditions specified in this protocol. 
[IP_ADDRESS]. Participant Preparation 
Administration day assessments (including vital signs and query for concomitant medications 
and adverse events) should be co mpleted. At least [ADDRESS_85795]-spectrum topi[INVESTIGATOR_78514] 5 minutes beginning approxim ately 15 minutes prior to the procedure. With 
the participant in a supi[INVESTIGATOR_2547], the eye and c onjunctival fornices should be irrigated with 5% 
ophthalmic povidone-iodine solution and the lids a nd surrounding orbital area should be prepped 
and draped according to the standard pr otocol detailed in the Procedure Manual. 
[IP_ADDRESS]. Study Treatment Location 
At the discretion of the inves tigator, Bimatoprost SR administ ration may be performed at an 
Ambulatory Surgical Center (ASC; free standing or hospi[INVESTIGATOR_78515]) or in the office setting (eg, in 
a procedure room with an operating microscope).  As a standard ASC technique, an intravenous 
catheter may be placed and intravenous sedati ves may be used at the discretion of the 
investigator and/or anesthesiologist. The ASC ma y have SOPs that require an electrocardiogram 
and/or a chest radiograph performe d prior to the procedure. A sepa rate standard consent to have 
the procedure at an ASC may be requi red per the SOPs at the facility. 
Sterile technique should be practiced at all times. 
[IP_ADDRESS]. Administration Technique 
Intracameral administration of Bimatoprost SR must be performed by [CONTACT_78555]. The 
principal investig[INVESTIGATOR_136]or [INVESTIGATOR_136] a site  may designate an ophthalmologist subinvestigator to perform the    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85796]. The eye is stabilized by [CONTACT_78556] a sterile to othed forceps or counter pressure  with a cotton tipped applicator 
as the needle is advanced through the cornea. The actuator button is depressed until an audible 
and/or palpable click is heard. The Bimatoprost SR implant should be visible exiting the needle 
bevel into the aqueous humor. The needle is then immediately removed from the AC, and the 
wound is checked for aqueous leakage. Following re moval of the lid speculum and sterile drape, 
additional drops of broad spectrum antibiotics should be applied. 
[IP_ADDRESS]. Immediate Posttreatment Observation 
Following Bimatoprost SR administration, the partic ipant is expected to sit upright and is kept 
for a minimum of [ADDRESS_85797] SR treated 
eye to ensure that the AC is formed prior to the participant being released. 
The participant will be supplied a bottle of topi[INVESTIGATOR_78516] 3 days (including the day of the administration) in the Bimatoprost SR 
treated eye and to follow up as per protocol. 
Prior to leaving the site, participants should be instructed to contact [CONTACT_78557] . If the participant re ports having experienced 
adverse events, these must be re corded on the appropriate eCRF. 
6.2. Preparation/Handling/Storage/Accountability 
Bimatoprost SR is loaded into the single-use applicator during manuf acturing and is provided 
within the applicator as a ster ile, finished product. Study site  personnel should notify Allergan 
immediately to advise or any situation in whic h the Bimatoprost SR applicator is defective. 
At selected site(s), licensed and marketed LUMIGAN 0.01% will be acquired in a multidose 
bottle by [CONTACT_78558] ’s instructions prior to dispensing to the 
participant. 
The study medications must be stored in a secu re area and administered /dispensed only to 
participants entered into the clin ical study, at no cost to the pa rticipant, in accordance with the 
conditions specified in this protocol. Only  assigned study personnel authorized by [CONTACT_78559]. Bima toprost SR must be stored in the original 
sealed foil pouch.  The investigator or designee must confirm a ppropriate temperature conditions have been 
maintained during transit for all study medicatio ns received and any di screpancies are reported 
and resolved before use of the study medications.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85798] be stored in a 
secure, environmentally controlled, and monito red (manual or automated) area in accordance 
with the labeled storage conditions with access lim ited to the investigator and authorized site 
staff. More details regarding storage conditi ons of study medications are available in the 
Procedure Manual. 
The investigator, institution, or  the head of the medical institution (where applicable) is 
responsible for study medication accountability, r econciliation, and reco rd maintenance (ie, 
receipt, reconciliation, a nd final disposition records). 
All used Bimatoprost SR applicators should be properly disposed of into a sharps container 
following the site's standard procedure and not physically returned to the depot. Malfunctioning 
applicators may be returned to the sponsor at the sponsor’s request. All unused Bimatoprost SR 
kits must be returned to the sponsor at th e termination of the study. Unit counts will be 
performed when Bimatoprost SR kits are retu rned, and all Bimatoprost SR kits must be 
accounted for.  At selected site(s) for particip ants assigned to LUMIGAN 0.01%, sites must ensure appropriate 
dispensing and documentation in source for the duration of the study. 
6.3. Measures to Minimize Bias: Randomization and Blinding 
Prior to initiation of study treatment, each pa rticipant who provides informed consent will be 
assigned a participant number that  will serve as the pa rticipant identification number on all study 
documents. This is an open-label study, and neither the investigator nor the participant will be masked to the 
assigned study treatment.    
The IWRS will dispense the appropriate Bima toprost SR medication kit(s) on Day 1. Study 
medication kits for Bimatoprost SR will be la beled with medication kit numbers. Sites will 
receive IWRS confirmation notifications for each transaction. All notif ications are to be 
maintained with the study source documents.  
The participant and the investigator will not be masked to the study treatment assignment for the 
duration of the study. However, delegated site staff collecting 24-hour IOP measurements will be 
masked to the study treatment and study eye. Par ticipants and unmasked site staff should be 
discouraged from discussing treatment assignmen ts with 24-hour IOP assessors. Hour [ADDRESS_85799] that specifie s the kit number of the 
IP administered to each participant, the eye receiving the treatmen t, and the date of 
administration. At selected site(s), participants will be assi gned to either Bimatopros t SR or LUMIGAN 0.01% 
in the study eye on Day 1 . Sites will provide 
LUMIGAN 0.01% to assigned participants on Da y [ADDRESS_85800] that specifies the eye receiving trea tment, and the start date of treatment.     

 
 
Approval Date :  
 20-Dec-[ADDRESS_85801] SR 10 µg in the study eye. Study treatment compliance will be assumed to be 100% 
when administration has been recorded in the eCRF. 
The study center will keep an accurate drug disposition record that specifies the amount of study 
treatment administered to each particip ant and the date of administration. 
Participants assigned to LUMIGAN 0.01% will be gin self-administratio n of LUMIGAN 0.01% 
once daily in the evening (at 20:00 ± 1 hour) starting with the evening dose on Day [ADDRESS_85802] use their evening dose of LUMIGAN 0.01% at 20:00 ± 1 hour, which will be documented in so urce. Please see the Procedure Manual for 
details. 
6.5. Concomitant Therapy 
Any medication or vaccine (including over-the-count er and/or prescription medicines; vitamins; 
herbal supplements, and/or cannabi s or other specific categories of interest) that the participant is 
receiving at the time of enrollment or receives during the study must be  recorded along with: 
 Indication 
 Dates of administration incl uding start and end dates 
 Dosage information including dose and frequency 
6.5.1.  Prohibited Interventions and Washout Before the Study 
All participants must provide informed consen t prior to beginning any drug washout for the 
purposes of inclusion in this study. Participan ts currently being treated with IOP-lowering 
medication(s) in either eye will begin washout of these medication(s) following completion of 
screening procedures. The screening and washout  periods may not be concurrent. The washout 
period will be up to 42 days depending on th e minimum washout period schedule below. 
If participants cannot discontinue  their prescribed therapy for up to 6 weeks to meet the washout 
period for study entry, the investigator may sw itch the participant’s me dication to one that 
requires a shorter washout interval during the washout of the original me dication ( Table 6–2 ). 
Nonetheless, the investigator should adhere to the m inimum washout period for all IOP-lowering 
medications used, as indicated in Table 6–2 . 
If, after initial washout, the IOP does not meet entry criteria and the investig ator believes this is 
due to inadequate washout, if time remains in the washout period he/she may perform additional 
washout, as long as the total was hout period does not exceed 42 days.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85803]-T-01-01 v3.0  Table 6–2 Minimum Washout Period by [CONTACT_78560] (eg, PI[INVESTIGATOR_78517]®, Carbachol, Pi[INVESTIGATOR_78518]®) 4 days 
Carbonic Anhydrase Inhibitors (topi[INVESTIGATOR_78519]) (eg, Diamox®, Trusopt®, Azopt®) 4 days 
Sympathomimetics (eg, PROPI[INVESTIGATOR_44466]®, Epi[INVESTIGATOR_78520]®) 14 days 
Alpha-agonists (eg, ALPHAGAN P, Iopi[INVESTIGATOR_5325]®) 14 days 
Beta-adrenergic blocking agents (eg, Timoptic®, BETAGAN®, Betoptic®, Betoptic-S®, 
Opti-Pranolol®, Ocupress®, Timoptic XE®) 28 days 
Rho-kinase inhibitors (eg, Rhopressa®, Glanatec®) 28 days 
Prostamides, prostaglandins and prostaglandin analogs, as well as combination products that include these medications (eg, LUMIGAN, Xalatan, Travatan, Rescula
®, GANFORT®) 28 days 
Combination therapy (for example, COMBIGAN® [28 days], Cosopt® [28 days], 
GANFORT® [28 days], Simbrinza® [14 days], Azarga® [28 days], Roclatan® [28 days], etc) Longest minimum 
duration of any 
component based on 
medication class 
For participants undergoing a washout, interim safety  evaluation(s) of IOP at any time during the 
washout period may be performed at the discretion of the investigator. 
Note: Medications should only be discontinued (was hed out) if the investigator feels that it is 
safe and appropriate, and if the participant is  willing to discontinue the medication for the 
duration of the study. If the medication cannot be discontinued, then the participant will not be 
eligible for study entry. 
6.5.2.  Permitted Treatments 
Ophthalmic Treatments 
The fellow eye will receive standard of care for IOP lowering, provided there is no known 
potential crossover effect to the study eye (eg, prostaglandin analogues, carbonic anhydrase inhibitors, laser or surgical procedures, etc) (see Section 6.5.4 for details on prohibited 
treatments). If the fellow eye requires laser or surgical treatment, it must be performed not less than [ADDRESS_85804] SR administration in the study eye.  
Intermittent use of artificial tear products is allowed if they are not taken ≤ [ADDRESS_85805] ophthalmic solution, and intermittent use of ocular decongestants or antihistamines is 
allowed if not taken: 
 Within [ADDRESS_85806] SR 
administration procedure 
 Within 2 days prior to the Week 8 vis it, through the completion of the 24-hour lab 
assessments     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85807] SR administration procedure. 
For participants assigned to LUMIGAN 0.01%, if the participant uses any other additional, 
permitted, topi[INVESTIGATOR_20718], the topi[INVESTIGATOR_78521](s) must be 
administered at least 5 minutes apart from the LUMIGAN 0.01% in the study eye. 
Use of postinjection topi[INVESTIGATOR_78522] (see Procedure Manual). Use of topi[INVESTIGATOR_78523] 1 through Day 7 following admini stration is allowed at  the investigator’s 
discretion. 
Implant Removal 
In the event that the Bimatoprost SR implant requ ires removal for significant safety reasons, this 
may be performed at the discretion of the inve stigator (see Procedure Manual for details). The 
investigator may contact [CONTACT_78561]. Note that in the event that the investigator performs an incisional su rgical procedure on the 
Bimatoprost SR implanted eye during which ocular fluid is to be removed, ocular fluid/implant 
samples may be collected for analysis at the i nvestigator’s discretion (s ee Procedure Manual for 
details). Systemic Medications 
The use of systemic NSAIDs is permitted. In addition, therapy considered necessary for the participant’s welfare may be given at the 
discretion of the investigator. If  concurrent medications may have an effect on study outcomes, 
these medications should be administered in dos ages that remain constant throughout the entire 
duration of the study. If the permissibility of a specific medica tion/treatment is in question, 
please contact [CONTACT_78562]. 
6.5.3.  Rescue Medicine 
In the event that the study eye IOP does not  meet or does not maintain IOP-lowering 
expectations, rescue IOP-loweri ng treatment (medication[s] or procedure[s] or both) can be 
initiated at the investigator’s discretion. Inadequate control of IOP should be confirmed at a 
subsequent visit (scheduled or unscheduled visit) not on the same day. Rescue treatment can be 
initiated at the investigator’s disc retion at any time during the study if it is in the best interest of 
the participant. Prior to completion of the M onth 12/Study Exit visit, the investigator will be 
expected to attest to the n eed for additional nonstudy IOP-lowering (rescue) treatment in the 
study eye for safety reasons.    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85808]-T-01-01 v3.0  6.5.4.  Prohibited Interventions During the Study 
The decision to administer a prohibited medicati on and/or treatment is done with the safety of 
the study participant as the primary consideratio n. When possible, Allergan should be notified 
before the prohibited medication/treatment is administered. 
During the study, participants should not participate in other investig ational drug or device 
studies. 
Nonstudy IOP-lowering Treatments 
The fellow eyes of participants will receive standard of care for IOP lowering, provided there is 
no crossover effect on the study eye. Use of any concurrent nonstudy IOP-lowering treatment in 
the fellow eye with a known potential effect on out comes (ie, alpha agonists and beta-adrenergic 
blocking agents) in the study eye is prohibited during the study.   
Contact [CONTACT_78563] 3 days and/or use of rigid gas permeable or hard contact [CONTACT_78564] 1 week prior to a scheduled  study visit or Day 1, and/or us e of contact [CONTACT_78565] [ADDRESS_85809] SR admini stration in the study eye,  is prohibited. From 
08:00 ± [ADDRESS_85810] IOP measurement of Sleep Lab visits ending at 
06:00 ± [ADDRESS_85811] lenses. For participants 
assigned to LUMIGAN 0.01%, contact [CONTACT_78566] 15 minutes following administration of LUMIGAN 0.01%. 
Other Treatments 
The following medications (or classes of medi cations) and treatment procedures are not 
permitted as concurrent therapy during the st udy through completion of the Month 12/Study Exit 
visit, unless the participant has already been treated with rescue IOP-lowering medication in the study eye: 
 Subconjunctival, sub-Tenon’s, intravitreal, or other ophthalmic injections of any 
medications in either eye 
 Use of any topi[INVESTIGATOR_78524] (except as described in Section 6.5.2) in the 
study eye 
 Surgical procedures in the study eye that  are not related to the Bimatoprost SR 
administration procedure  
 Use of bimatoprost for hypotrichosis during the study period in the study eye 
 Systemic use of carbonic anhydrase inhibitors  
 Any systemic regimen of beta-b locker containing medications     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85812]-T-01-01 v3.0   Use of corticosteroids in  the study eye (except as described in Section 6.5.2 for 
postinjection use) or systemically during the study or historical use prior to Baseline 
within: 
o 3 years: intraocular fluocinolone acetonide 
o 6 months: intraocular corticosteroid(s) other than fluocinolone; any injectable 
periocular or sub-Tenon’s/subc onjunctival corticosteroid 
o 2 months: systemic (eg, oral, intramuscular, intrav enous) or topi[INVESTIGATOR_78510]  
o 2 weeks: dermal corticosteroid applied to skin of the eyelid(s), around the eye, 
or adnexa 
6.6. Dose Modification 
Dose modification is not applicable. 
6.7. Treatment after the End of the Study 
No interventions after th e end of the study are planned; participants will be treated per standard 
of care by [CONTACT_78567]. 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
A premature discontinuation from study treatment will occur if a participant who signs the ICF 
and receives study treatment ceas es participation in the study, regardless of circumstances, 
before the completion of the protocol-defined study procedures. 
Notification of early participant discon tinuation from the study and the reason for 
discontinuation will be made to the sponsor and will be clearly documented on the appropriate 
eCRF. 
Reasons for discontinuation from the study treatme nt and/or the study may include the following 
commonly used or other acceptable terms:      
 
 
Approval Date :  
 20-Dec-[ADDRESS_85813] ease see Section 6.5.2 for guidance on im plant removal and Section 7.2 for follow up 
requirements for participant discontinuation in the event the implant is removed. 
7.2. Participant Discontinuation/Withdrawal from the Study 
 A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of  the investigator for safety, behavioral, 
compliance, or administrative reasons. 
 If a participant develops (or has an exacer bation of) a medical c ondition that, in the 
opi[INVESTIGATOR_871], would put the part icipant at an unacceptable medical risk by 
[CONTACT_78568],  the participant will be withdrawn from the study. 
 If the participant withdraws consent for disclo sure of future information, the sponsor may 
retain and continue to use a ny data collected before such  a withdrawal of consent. 
 If a participant withdraws from the study, he /she may request destruction of any samples 
taken and not tested, and the investigator must document this in the site study records.    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85814]-T-01-01 v3.0   Participants assigned to and treated with Bimatoprost SR who have received nonstudy 
IOP-lowering treatment (rescue) in the study ey e, will be followed for the duration of the 
study through the Month 12/Exit visit. If the implant has been removed, the participant 
may discontinue the study if based on invest igator assessment the eye is in stable 
condition, at which time they should comp lete the Month 12/Exit visit procedures. 
Notification of early participant discon tinuation from the study and the reason for 
discontinuation will be made to Allergan  and will be clearly documented on the 
appropriate case report form. If participants discontinue before Month 12/Exit, the site 
should complete all procedures for the Month 12 /Exit visit at the par ticipant’s last visit. 
The investigator should consider  withdrawing a participant from  the study early if any of the 
following criteria are met: 
 Participant develops (or has an exacerbation of ) a medical condition that, in the opi[INVESTIGATOR_13046], compromises the participant’s ability to participate in the study 
 Participant is unwilling or unable to con tinue to comply with study procedures 
 Participant is unwilling or unabl e to continue in the study 
Whenever possible, the decision to withdraw a participant from the study or study treatment 
should be discussed with Allergan. 
7.3. Lost to Follow Up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
 The site must attempt to contact [CONTACT_78569] d/or should continue in the 
study. 
 Before a participant is deemed lost to follow-up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possi ble, 3 telephone calls, and if 
necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_78570]’s 
medical record. 
 Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85815]-T-01-01 v3.0  8. Study Assessments and Procedures 
 A detailed listing of study a ssessments by [CONTACT_78571] 8. 
 Study procedures and their timing ar e summ arized in the SoA (Section 1.3). Protocol waivers 
or exemptions are not allowed. 
 Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the part icipant should continue or discontinue study 
treatment. 
 Adherence to the study design requirements , including those specified in the SoA 
(Section 1.3), is essential and re quired for study conduct. 
 All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened a nd to confirm eligibility or record reasons for 
screening failure, as applicable. 
Participants who complete all re gularly scheduled study visits shou ld have 9 study office visits, 
2 sleep lab visits, and 1 phone call.  The schedule includes the following: 
 Screening (up to 60 days); Washout Period of up to 42 days; and Baseline (Office visit and 
Sleep Lab visit) 
 Day 1; Day 2 Safety visit  
 Day 8 phone call 
 Weeks 8 (Office and Sleep Lab visit) and 16; and Months 6, 9, and 12/Study Exit visits  
8.1. Efficacy Assessments 
Efficacy assessments are to be completed as outlined in the SoA (Section 1.3). 
The primary and secondary efficacy measures of  IOP collected over [ADDRESS_85816] 2 measurements differ by > 
[ADDRESS_85817] 2 measurements differ by ≤ [ADDRESS_85818] 2 measurements is > 1 mm Hg, the IOP for the given eye will be the median of the 3 readings. 
The 24-hour IOP values collected at the Baseline Sleep Lab visit and Week 8 Sleep Lab visit will 
be performed at 08:00 ± 30 minutes, 10:00 ± 30  minutes, 12:00 ± 30 minutes, 
14:00 ± 30 minutes, 16:00 ± 30 minutes, 18:00 ± 30 minutes, 20:00 ± 30 minutes, 
22:00 ± 30 minutes, 00:00 ± 30 minutes, 02: 00 ± 30 minutes, 04:00 ± 30 minutes, and 
06:00 ± 30 minutes. Diurnal IOP measurements are defined as the IOP values collected between 08:00 ± 30 minutes to 22:00 ± [ADDRESS_85819] urnal IOP measurements are defined as the     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85820]-T-01-01 v3.0  IOP values collected between 00:00 ± 30 minutes  to 06:00 ± [ADDRESS_85821] 
90 minutes after the previous time point. Diurnal IOP measurements performed at Baseline Sleep 
Lab visit and Week 8 Sleep Lab visit will be perform ed with the participants in a supi[INVESTIGATOR_2547] 
≥ [ADDRESS_85822] then sitting  ≥ [ADDRESS_85823]. Nocturnal IOP measurements will be 
collected with the participants ≥ [ADDRESS_85824] in a supi[INVESTIGATOR_78525]. Lights in individual 
sleep rooms will be turned off at 23:00 and nocturnal IOP measurements will be performed 
under dim lighting with monitoring of  the participant’s sleep status . At least 2 individuals, one 
being of the same sex as the participant, will be present in individual participant rooms for nocturnal assessments. At the Week 8 Sleep La b visit, participants assigned to LUMIGAN 
0.01% must continue their evening dose of LUMIGAN 0.01% at 20:00 ± [ADDRESS_85825] 
be taken not to unmask the IOP assessor. Please see Procedure Manual for additional details.  
Other efficacy measures assess Hour 0 IOP a nd time to initial use of nonstudy IOP-lowering 
treatment. All Hour 0 IOP examinations will be scheduled at 08:00 ± [ADDRESS_85826] 2 measurements differ by > [ADDRESS_85827] 2 measurements differ by ≤  [ADDRESS_85828] 
2 measurements is > 1 mm Hg, the IOP for the given eye will be the median of the 3 readings. All Hour 0 IOP examinations will be performed with the participants in a sitting position. 
8.2. Safety Assessments 
Planned timepoints for all safety assessm ents are provided in the Schedule of Activities 
(Section 1.3). 
8.2.1.  Physical Examinations 
The participant will be examined by [CONTACT_78572] a modified physical 
examination, which may include assessments of: general appearance; head , eyes, ears, nose, and 
throat; heart/cardiovascular; lungs; abdomen; ne urologic; extremities; back; musculoskeletal; 
lymphatic; and skin. Height and weight will also be measured and recorded. 
8.2.2.  Vital Signs 
Vital signs will be assessed as follows: 
 Temperature, pulse rate, and BP will be assessed. 
 BP and pulse measurements will be assessed w ith participants in a seated position with a 
completely automated device. Manual techniques will be used only if an automated device is 
not available. 
 Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_85829] in a 
seated position.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85830] may 
also be performed at any other visit, at the investig ator’s discretion. At each visit, the investigator 
should discuss contracep tive use compliance with  WOCBP females of childbearing potential 
(see Appendix 7  for more details). 
8.2.4.  Clinical Safety Laboratory Assessments 
See Appendix [ADDRESS_85831] of clinical laboratory tests to be performed and the Schedule of 
Activities (Section 1.3) for the tim ing and frequency. 
At Screening, the investigator or  qualified subinvestigator will assess the clinical significance of 
any values outside the reference ranges provi ded by [CONTACT_25699], and participants with 
abnormalities judged to be clinically signi ficant will be excluded from the study. 
8.2.5.  Ocular Safety Assessments 
[IP_ADDRESS]. Macroscopic Conjunctival Hyperemia Assessment 
Macroscopic conjunctival hyperemia will be asse ssed using the appropriate assessment guide 
(see the Procedure Manual for further details). 
[IP_ADDRESS]. Best-corrected Visual Acuity 
Visual acuity tests will be perfor med at all visits except on Day [ADDRESS_85832] refraction using Snellen equivalent with a logMar chart (see Procedure Manual) will be 
performed at Screening, Baseline (Office visit), and Month 12/Study Exit. At all other visits, the 
visual acuity technician will use the last manife st refraction performed and determine the Snellen 
equivalent visual acuity using the logMar chart. If there is a 2-line or more reduction in visual 
acuity from the last best-corrected visual acuity performed, a repeat manifest refraction in both 
eyes and BCVA will be performed. See the Procedure Manual for further details. 
[IP_ADDRESS]. Visual Field 
Visual field examinations will be assessed usi ng automated perimetry (using either Humphrey 
24-[ADDRESS_85833], or Octopus G1 or 24-2 and dynamic or 
normal strategy). The same test methodology must  be used throughout th e entire study for a 
given participant. If dilation is required to perfor m this test, then the visu al field test should be 
performed after gonioscopy/angle assessment or with the scheduled dilated exams, if applicable. 
See the Procedure Manual for further details.  
[IP_ADDRESS]. Specular Microscopy 
Endothelial cell density will be assessed usi ng specular microscopy performed on the central 
cornea. The determination of central endothelial cell density for study entry as well as study visit     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85834] be used throughout the 
study for a given participant.  
[IP_ADDRESS]. Biomicroscopy 
Biomicroscopic examinations will be performed using a slit lamp. The examinations will include 
evaluation of the condition of the eyelids, conjun ctiva, cornea, AC (with Van Herick anterior 
chamber depth assessment at Screening only), iris /pupil, and lens (lens assessment is performed 
using the modified AREDS procedure and is collected on dilated exam ination days through a 
dilated pupil, using the slit-lamp biomicroscope . Please see the Procedure Manual for details). 
[IP_ADDRESS]. Gonioscopy/Angle Assessment 
Gonioscopic examinations will be performed by [CONTACT_78573]. At Screening and the Baseline  Office visits, the investigator’s eligibility 
assessments must confirm participant eligibility for participation in th e study. In subsequent 
gonioscopic examinations during the study, the investigator will evaluate the inferior 
iridocorneal angle and the Bimatoprost SR implant. 
[IP_ADDRESS]. Pachymetry 
Corneal thickness using ultrasound (c ontact) pachymetry will be performed on the central cornea. 
The same instrument should be used throughout the study for a given participant. Pachymetry 
may be performed any time after non-contact [CONTACT_78538]. See the Procedure Manual for further 
details. 
[IP_ADDRESS]. Dilated Ophthalmoscopy 
The stereoscopic fundus assessments should be conducted through a dilated pupil. The 
examinations will include evaluation of the macula, vitreous, and retina. [IP_ADDRESS]. Optic Disc Examination 
The cup/disc ratio and presence of optic disc  pathology will be determ ined using stereoscopic 
evaluation. 
8.3. Adverse Events and S erious Adverse Events 
The definitions of an AE or SAE can be found in Appendix 3.  
AEs may be reported by [CONTACT_2299] (or, when  appropriate, by a caregiv er, surrogate, or the 
participant’s legally authorized representative). 
Additionally, the investigator and any qualified designees are responsible for detecting, 
documenting, and recording events that meet the definition of an AE or SAE and remain 
responsible for following up AEs that are serious, considered related to the study treatment or study procedures, or that caused the participant to discontinue the study treatment or the study 
(see Section 7).     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85835]-T-01-01 v3.0  8.3.1.  Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event Information 
All AEs and SAEs from the signing of the ICF un til the study exit visit will be collected at the 
timepoints sp ecified in the SoA (Section 1.3), and as observed or reported spontaneously by 
[CONTACT_19288]. 
Medical occurrences that begin before the star t of study treatment, but after obtaining informed 
consent will be recorded in the AE section of the eCRF. 
All SAEs will be record ed and reported to the sp onsor or designee within 24 hours, as indicated 
in Appendix 3 . The investigator will subm it any update d SAE data to the sponsor within 
24 hours of it being available. 
Investigators are not obligated to  actively seek AE or SAE information after conclusion of the 
study participation. However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she cons iders the event to be 
reasonably related to the study intervention or study participation, the investigator must promptly 
notify the sponsor. The method of recording, evaluating, and a ssessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3. 
8.3.2.  Method of Detecting Adverse Events and Serious Adverse Events 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participan t is the preferred method to inquire about 
AE occurrences. 
8.3.3.  Follow Up of Adverse Events and Serious Adverse Events 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All AEs/SAEs will be followed until reso lution, stabilization, the 
event is otherwise explained, or the participan t is lost to follow-up (as defined in Section 7.3). 
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_41443]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, hist opathological examinations, or 
consultation with other h ealth care professionals. 
If a participant dies during participation in th e study or during a recognized follow-up period, the 
investigator will provide Allergan with a copy of any postmortem findings including 
histopathology. 
New or updated information will be record ed in the originally completed eCRF. 
The investigator will submit any updated SAE data  to sponsor or designe e within 24 hours of 
receipt of the information.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85836]-T-01-01 v3.0  8.3.4.  Regulatory Reporting Requirements for Serious Adverse Events 
 Prompt notification by [CONTACT_78574] 
a study intervention under clinic al investigation are met.  
 The sponsor has a legal responsibility to notify both the local re gulatory authority and 
other regulatory agencies about the safe ty of a study intervention under clinical 
investigation. The sponsor will comply w ith country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs/ IECs, and investigators.  
 Investigator safety reports must be prepar ed for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary. 
 An investigator who receives an investigator  safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from th e sponsor will review 
and then file it along with the investigator’s  brochure and will notify the IRB/IEC, if 
appropriate according to local requirements. 
8.3.5.  Pregnancy 
 If a pregnancy is confirmed after the part icipant has received the study treatment, the 
participant may choose to exit the study after appropriate safety follow-up or to remain in 
the study for all safety and efficacy follow up assessments through the study exit visit. 
 Details of all pregnancies in female particip ants will be collected from the signing of the 
ICF and through the duration of the pregnancy. 
 If a pregnancy is reported, the investigator  should inform Allergan within 24 hours of 
learning of the pregnancy and should follow the procedures outlin ed in Appendix 7 . 
 Abnormal pregnancy outcomes (eg, spontaneous or  elective abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs. 
8.3.6.  Medication Errors 
Medication error refers to any uni ntended error in the dose strength and/or administration of the 
study treatment as per instructi ons in the protocol and/or th e Procedure Manual. Medication 
errors generally fall into the categories as follows: 
 Wrong study drug 
 Wrong dose strength 
 Wrong route of administration 
 Wrong participant (ie, not administered to  the intended participant) or wrong eye 
 Study medication expi[INVESTIGATOR_78526] :  
 20-Dec-[ADDRESS_85837]-T-01-01 v3.0  8.4. Treatment of Overdose 
Not applicable. 
8.5. Pharmacokinetics 
Pharmacokinetic parameters are not evaluated in this study. 
8.6. Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study. 
8.7.  Genetics 
Genetics are not evaluated in this study. 
8.8. Biomarkers and Other Assessments 
8.8.1.  Anterior Segment Imaging 
At selected sites/selected participants only, anterior segment imaging may be performed using 
Allergan-approved instruments. Please see th e Procedure Manual for further details. The 
participant’s decision about whether to allow anterior segment imaging will not affect their 
eligibility for participation in the study. 
8.9. Health Economics 
Health economics are not evaluated in this study. 
9. Statistical Considerations 
Two database locks are planned for this study. The first database lock, for the primary and 
secondary efficacy endpoint analysis, will occur when 100% of participants have completed the 
primary visit (ie, Week 8 Sleep Lab visit) or prematurely discontinued prior to the Week [ADDRESS_85838] completed the study at Month 12 or prematur ely discontinued from the study. 
Analyses will be performed after each lock: the primary and sec ondary efficacy analysis results 
are based on the first database lock, and the anal yses based on the second database lock provides 
further efficacy and safety information. Prior to the first database lock a detailed analysis plan 
will be finalized.  
9.1. Statistical Hypotheses 
There are no statistical hypotheses for this study.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85839]-T-01-01 v3.0  9.2. Sample Size Determination 
The sample size is based on practical consider ations. Approximately 35 participants will be 
enrolled: [ADDRESS_85840] SR cohort and 5 in the LUMIGAN 0.01% cohort. 
Twenty-five to [ADDRESS_85841] SR. This 
assumes a premature discontinuation rate of  up to 33%. Participants who prematurely 
discontinue from the study will not be replaced. 
Participants will be assigned to the Bi matoprost SR or LUMIGAN 0.01% cohort by [CONTACT_1275]. 
9.3. Populations for Analyses 
Safety Analysis Set (SAF): All participants  who have received study intervention (ie, 
Bimatoprost SR administration or LUMIGAN 0.01%) wi ll contribute to the SAF. All safety data 
collected from these participants will be included in the SAF.  
Full Analysis Set (FAS): All par ticipants who have received study intervention (ie, Bimatoprost 
SR administration or LUMIGAN 0.01%) with at least 1 postbaseline IOP assessment will 
contribute to the FAS. All efficacy data collected from these participants will be included in the 
FAS with the following exception:  
 To avoid confounding of efficacy data, IOP measurements obtained after initiating the use 
of nonstudy rescue IOP-lowering treatment (medi cation[s] or procedure[ s] or both) in an 
eye will be excluded from FAS.   
9.4. Statistical Analyses 
In general, continuous variables will be su mmarized by [CONTACT_9084] (Bimatoprost SR or LUMIGAN 
0.01%) for number of participants, mean, standard deviation, median, first quartile, third quartile, 
minimum, and maximum values. Categorical va riables will be summarized by [CONTACT_78575]. 
An SAP will be developed and finalized before th e first database lock. The details of the planned 
statistical analyses will be provided in the SA P. This section is a summary of the planned 
statistical analyses. 
9.4.1.  Efficacy Analyses 
The efficacy analyses will be based on the FAS.   
[IP_ADDRESS]. Analysis Endpoints 
The primary efficacy endpoint is the time-matche d IOP change from baseline at the Week [ADDRESS_85842] SR cohort.       
 
 
Approval Date :  
 20-Dec-[ADDRESS_85843]-T-01-01 v3.0  As described in Section 8.1, the m edian of the IOP measurements at each timepoint will be the 
value used for analysis for the study eye.  
[IP_ADDRESS]. Primary Efficacy Analyses 
Sleep Lab visit collected IOP raw values a nd the corresponding time-matched change from 
baseline in IOP will be summarized descriptively by [CONTACT_78576]. Ninety-five percent CIs based on a paired t-test will be provided for the mean time-matched IOP change from baseline.  Mean IOP and mean time-matched IOP change 
from baseline across time during diurnal/wake  period and nocturnal/s leep period will be 
presented graphically for the study ey e in the Bimatoprost SR cohort.  
[IP_ADDRESS]. Secondary Efficacy Analyses 
IOP fluctuation will be evaluated by [CONTACT_78577]/wake period and nocturna l/sleep period, as well as over a 24-hour period in the 
Bimatoprost SR cohort. The range of IOP at baseline and Week 8, as well as the change from baseline to Week 8 in IOP range will be summarized descriptively.   
[IP_ADDRESS]. Other Efficacy Analyses 
Other efficacy analyses will include descriptive summary for IOP (Hour 0) values at baseline 
with corresponding change from baseline by [CONTACT_22986] t through Month 12/Study Exit. In addition,  
time from Day 1 to initial use of nonstudy rescue  IOP-lowering treatment (medication[s] or 
procedure[s] or both) in the study eye will be  analyzed using Kaplan-Meier methods.   
Summary statistics calculating change from base line in IOP will also be presented for the 
LUMIGAN 0.01% cohort. 
9.4.2.  Safety Analyses 
The safety analyses will be performed using the safety analysis set and will be fully defined in 
the SAP. General safety parameters will incl ude AEs (including pregnancy) and vital signs. 
Ocular safety parameters will include visual fields, best-corrected visual acuity, conjunctival 
hyperemia, biomicroscopy, dilated ophthalmos copy (including optic disc assessment), 
pachymetry, gonioscopy, and specular microscopy. 
Ocular AEs and safety variables will be tabulat ed by [CONTACT_78578], and 
nonocular safety variables will be summarized at the participant level.  
[IP_ADDRESS]. Adverse Events 
An AE will be considered a TEAE if the AE began or worsened (increased in severity or became 
serious) on or after the date (and time, if known) of the first admi nistration of study treatment.  
An AE will be considered a treatment-emergent SAE if it is a TEAE that additionally meets any 
SAE criterion.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85844]-T-01-01 v3.0  MedDRA nomenclature will be used to code AEs. Adverse events will be coded from the 
verbatim text into PT and SOC. AEs will be collected for both eyes and will be displayed 
separately where appropriate. Ocular AEs and safety variables will be summarized by [CONTACT_78579], and nonocular safety  variables will be summarized by [CONTACT_3445]. 
The number and percentage of participants re porting AEs will be tabulated by [CONTACT_78580]. Participants with multiple occurrences of a PT will be counted once in the 
calculation of the rate for that PT. Similarly, pa rticipants with multiple events within an SOC 
will be counted once in the inci dence rate for that SOC.  
Summary tables will be generated for all AEs rega rdless of causality as well as treatment-related 
AEs for the entire study. Related AEs will be di splayed as those related to study treatment or 
procedures. Summaries will also be displayed by [CONTACT_926]. 
[IP_ADDRESS]. Vital Signs 
Descriptive statistics for vital signs (systoli c and diastolic blood pressure, pulse rate, and 
temperature) at Baseline and changes from Baseline at each assessment will be presented by 
[CONTACT_9084] .  
9.5. Interim Analyses 
Two database locks will occur as described under Section 9. Analyses will be performed after 
each lock. The primary and secondary efficacy analysis based on the first database lock will be considered as final analysis. The analyses base d on the second database lock provide further 
efficacy and safety information. 
Additional safety analyses may be periodically  performed based on relevant data snapshots.   
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85845]-T-01-01 v3.0  10. Supporting Documentation and Operational Considerations 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
10.1.1. Regulatory and Ethical Considerations 
 This study will be conducted in accordance w ith the protocol and with the following: 
o Consensus ethical principles derived fr om international gui delines including the 
CIOMS International Ethical Guidelines 
o Applicable ICH/ISO GCP guidelines 
o Applicable laws and regulations 
 The protocol, protocol amendments, ICF, i nvestigator’s brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the study is initiated 
 Any amendments to the protocol will requir e IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to e liminate an immediate 
hazard to study participants.  
 The investigator will be re sponsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC 
o Notifying the IRB/IEC of SAEs or other sign ificant safety findings as required by 
[CONTACT_1744]/IEC procedures 
o Providing oversight of the overall conduct of the study at the site and adherence to 
requirements of applicable local regulations, for example 21 CFR, ICH guidelines, the IRB/IEC, and European regulation 536/ 2014 for clinical studies (if applicable) 
10.1.2. Financial Disclosure 
Investigators and subinvestigators will provide th e sponsor with sufficient, accurate financial 
information as requested to allow the sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appr opriate regulatory author ities. Investigators are 
responsible for providing information on financial interests during the cour se of the study and for 
1 year after completion of the study.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85846]-T-01-01 v3.0  10.1.3. Informed Consent Process 
 The investigator or his/her representative will explain the nature  of the study to the 
participant or his/her legally authorized repr esentative and answer all questions regarding 
the study.  
 Participants must be informed that their part icipation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 
50, local regulations, ICH guidelines, HIPAA requirements, where applicable, and the 
IRB/IEC or study center.  
 The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in th e study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF. 
 Participants must be re-consented to the most  current version of th e ICF(s) during their 
participation in the study.  
 A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative.  
10.1.4. Data Protection 
 Participants will be assigned a unique identifier. Any participant records or datasets that 
are transferred to the sponsor will contain th e identifier only; participant names or any 
information that would make the participan t identifiable will not be transferred.  
 The participant must be informed that his/her personal study-related data will be used by [CONTACT_78581]. The level of disclosure must also 
be explained to the participant.  
 The participant must be informed that his/her medical records may be examined by [CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
10.1.5. Posting Clinical Study Data 
 Study data and information may be published in  nonpromotional, peer-reviewed publications 
either by [CONTACT_78583] s ponsor with sponsor permission.  
 Clinical study reports, safety updates, and a nnual reports will be pr ovided to regulatory 
authorities as required. 
 Company-sponsored study information and tabul ar study results will be posted on the US 
National Institutes of Health's  website www.ClinicalTrials.gov  and other publicly accessible 
sites.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85847]-T-01-01 v3.0  10.1.6. Data Quality Assurance 
 All participant data relating to the study will be recorded on printed or eCRFs unless 
transmitted to the sponsor or designee electronica lly (eg, laboratory data). The investigator 
is responsible for verifying th at data entries are accurate and correct by [CONTACT_18027].  
 The investigator must maintain accurate do cumentation (source data) that supports the 
information entered in the CRF.  
 The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
 The sponsor or designee is res ponsible for the data management of this study including 
quality checking of the data.  
 Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_78584] e accurate, complete, and verifiable from 
source documents; that the safety and rights of  participants are being protected; and that 
the study is being conducted in accordance with  the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
 Records and documents, including signed ICFs , pertaining to the conduct of this study 
must be retained by [CONTACT_78585]. No records 
may be destroyed during the retention period without the written a pproval of the sponsor. 
No records may be transferred to another locat ion or party without wr itten notification to 
the sponsor.  
10.1.7. Source Documents 
 Source documents provide evidence for the exis tence of the particip ant and substantiate 
the integrity of the data collected. Source documents are filed at the investigator’s site. 
 Data reported on the CRF or entered in th e eCRF that are transcribed from source 
documents must be consistent with the sour ce documents or the discrepancies must be 
explained. The investigator may need to re quest previous medical records or transfer 
records, depending on the study.  
 Definition of what constitutes source data can  be found in Section 4.0 of ICH E6, Good 
Clinical Practice: Consolidated Guidance and must follow ALCOA, ie, records must be 
attributable, legible, contempor aneous, original, and accurate. 
10.1.8. Study and Site Closure 
The sponsor or designee reserves the right to close th e study site or terminate the study at any 
time for any reason at the sole discretion of th e sponsor. Study sites will be closed upon study 
completion. A study site is considered closed  when all required documents and study supplies 
have been collected and a study-site  closure visit has been performed.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85848] udy-site closure at any time, pr ovided there is reasonable cause 
and sufficient notice is given in ad vance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]: 
 Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the s ponsor’s procedures, or GCP guidelines 
 Inadequate recruitment of participants by [CONTACT_093] 
 Discontinuation of further study intervention development 
10.1.9. Publication Policy 
 Allergan as the sponsor has proprietary intere st in this study. Authorship and manuscript 
composition will reflect joint cooperation betw een multiple investig ators and sites and 
Allergan personnel. Authorship will be established prior to the writ ing of the manuscript. 
As this study involves multiple centers, no indi vidual publications will be allowed prior to 
completion of the final report of the multicen ter study except as agreed with Allergan. 
 The sponsor will comply with the requirem ents for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. 
 Authorship will be determined by [CONTACT_14346]. 
10.1.10. Compliance with Protocol 
The investigator is responsible for compliance wi th the protocol at the investigational site. A 
representative of the sponsor will make frequent contact [CONTACT_78586]/her 
research staff and will conduct regular monitoring visits at the site to review participant and 
study treatment accountability records for complian ce with the protocol. Protocol deviations will 
be discussed with the investigator upon identification. The use of the data collected for the participant will be discussed to determine if th e data are to be included in the analysis. The 
investigator will enter data that may be excl uded from analysis as defined by [CONTACT_78587]. Signifi cant protocol deviations will  be reported to the IRB/IEC 
according to the IRB/IEC’s reporting requirements.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85849]-T-01-01 v3.0  10.2. Appendix 2: Clinical Laboratory Tests 
The tests detailed in Table 10-1  will be perform ed by a central laboratory or designated regional 
facility, including any repeat laboratory tests. 
Protocol-specific requirements for inclusion or ex clusion of participants are detailed in Section 5 
of the protocol. Refer to the Central Laboratory Manual for further details regarding central 
laboratory collection and shipment procedures. 
Local laboratory results are only required in the event that the central laboratory results are not 
available in time for either study treatment admi nistration and/or respons e evaluation. If a local 
sample is required, it is important that the sample  for central analysis is obtained at the same 
time. Additionally, if the local laboratory results are used to make either a study treatment 
decision or response evaluation, the resu lts must be entered into the eCRF. 
Laboratory test results will be forwarded from the central laboratory or designated regional facility to the study site and to Allergan or its designee. Addi tional tests may be performed at any 
time during the study as determined necessary by [CONTACT_11006]. 
The investigator or qualified s ite personnel must review all laboratory results for any adverse 
events. Laboratory test results that represent adverse events should be reflected on an adverse 
event eCRF page. 
Evaluation and management of abnormal laborat ory results should be conducted according to 
local site practice. 
     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85850]-T-01-01 v3.0  Table 10-1 Protocol Required Safety Laboratory Assessments 
Laboratory 
Assessmentsa Parameters 
Hematology Platelets   RBC indices: 
MCV 
MCH 
MCHC 
Morphology WBC count with differential 
(absolute): 
Neutrophils 
Bands 
Lymphocytes Monocytes 
Eosinophils 
Basophils RBC count 
Hemoglobin 
Glycated hemoglobin 
Hematocrit 
Serum Chemistry BUN, uric acid Potassium AST Total, direct, and 
indirect bilirubin 
 Creatinine Sodium ALT Total protein 
 Creatinine kinase Magnesium, 
phosphorus Bicarbonate Total cholesterol 
 Glucose Calcium Alkaline 
phosphatase Chloride, albumin 
Routine 
Urinalysis  Specific gravity 
 pH, glucose, protein, blood, ketones, bilirub in, urobilinogen, nitrite, leukocyte esterase 
 Clarity, color, pr esence of blood 
 Microscopic examination (W BCs, RBCs, casts, bacteria, crystals, epi[INVESTIGATOR_1663]) 
a No laboratory assessmen ts require fasting. 
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85851]-T-01-01 v3.0  10.4. Appendix 4: Abbreviations 
 
Abbreviation/Term Definition 
ABMD Anterior Basement Membrane Disease 
AC anterior chamber 
AE adverse event 
AGIS Advanced Glaucoma Intervention Study 
ALT Alanine aminotransferase  
AMD age-related macular degeneration 
AREDS Age-related Eye Disease Study 
ASC ambulatory surgical center 
AST Aspartate aminotransferase  
BP blood pressure 
BUN blood urea nitrogen 
CFR Code of Federal Regulations  
CI  confidence interval 
CIOMS Council for International Organizations of Medical Sciences 
eCRF electronic case report form 
EU European Union 
FAS full analysis set 
FDA Food and Drug Administration 
FSH follical stimulating hormone 
GCP Good Clinical Practice 
HIPAA Health Insurance Portability and Accountability Act 
HRT hormone replacement therapy 
ICF informed consent form 
ICH International Council for Harmonisation 
IEC independent ethics committee 
IOL intraocular lens implant 
IOP intraocular pressure 
IP investigational product 
IRB  institutional review board 
ISO International Organization for Standardization 
IWRS interactive web response system 
LT laser trabeculoplasty 
MCHC mean corpuscular he moglobin concentration 
MCH mean corpuscular hemoglobin    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85852]-T-01-01 v3.0  Abbreviation/Term Definition 
MCV mean corpuscular volume 
MedDRA Medical Dictionary for Regulatory Activities  
MIGS minimally invasive glaucoma surgery 
NSAID nonsteroidal anti-inflammatory drugs 
OAG open-angle glaucoma 
OHT ocular hypertension 
OU both eyes 
PLA polylactic acid 
PLGA polylactic-co-glycolic acid  
POAG primary open-angle glaucoma 
PT preferred term 
RBC red blood cell 
SAE serious adverse event 
SAF safety analysis set 
SAP statistical analysis plan 
SLT selective laser trabeculoplasty  
SoA schedule of activities 
SOC system organ class 
SOP standard operating procedure 
SR sustained release 
S[LOCATION_003]RS suspected unexpected serious adverse reactions  
TEAE treatment-emergent adverse event 
US/[LOCATION_003] [LOCATION_002] 
WBC white blood cell 
WHO World Health Organization 
WOCBP woman of childbearing potential 
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85853]-T-01-01 v3.0  10.5. Appendix 5: Standard Discontinuation Criteria 
This table provides participant discontinuation cr iteria for this protocol . CDISC terminology is 
used, and thus subject  or patient is used instead of participant  (as used elsewhere in this 
protocol). These terms are interchangeable.   
CDISC Submission Value CDISC Definition 
Adverse event Any untoward medical occurren ce in a patient or clinical 
investigation subject administer ed a pharmaceutical product and 
which does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, 
whether or not related to the medicinal (investigational) product. 
For further information, see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting (modified from ICH E2A) Synonyms: side effect, 
adverse experience. See also serious adverse event, serious adverse experience. (CDISC glossary) 
Completed To possess every necessary or norm al part or com ponent or step; 
having come or been brought to a conclusion (NCI) 
Death The absence of life or state of being dead (NCI) 
Disease relapse The return of a di sease after a period of remission 
Failure to meet randomization criteria An indication that the subject has been unable to fulfill/satisfy the criteria required for assignment into a randomized group 
Lack of efficacy The lack of  expected or desired effect  related to a therapy (NCI) 
Lost to follow-up The loss or lack of continuation of a subject to follow-up 
Non-compliance with study drug An indication that a subject has not agreed with or followed the instructions related to the study medication (NCI) 
Other Different than the one(s) previously specified or mentioned (NCI) 
Physician decision A position, opi[INVESTIGATOR_1649], or judgment reached after consideration by a physician with reference to subject (NCI) 
Pregnancy Pregnancy is the state or condition of having a developi[INVESTIGATOR_78527] (uterus), after union of an ovum and spermatozoon, during the period from conception to birth. (NCI) 
Progressive disease A disease process that is increasing in extent or severity (NCI) 
Protocol deviation An event or decision that stands in contrast to the guidelines set out by [CONTACT_760] (NCI) 
Recovery A healing process and/or an outcome implying relative health. The term is typi[INVESTIGATOR_78528] t of direct and indirect effects of 
sickness or injury. (NCI) 
Screen failure The potential subject who does not meet one or more criteria required for participation in a trial 
Site terminated by [CONTACT_78588] a clinical study was stopped at a particular site by [CONTACT_23662] (NCI)    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85854]-T-01-01 v3.0  CDISC Submission Value CDISC Definition 
Study terminated by [CONTACT_78588] a clinical study was stopped by [CONTACT_23662] (NCI) 
Technical problems A problem with some technical asp ect of a clinical study, usually 
related to an instrument (NCI) 
Withdrawal by [CONTACT_78589] a study participant has removed itself from the study (NCI) 
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85855]-T-01-01 v3.0  10.6. Appendix 6: Study Tabular Summary 
This table is intended for use in posting study informa tion to registries (eg, ClinicalTrials.gov).   
Parameter Group Parameter Value 
Trial information Trial Title An Evaluation of the 24-Hour IOP-lowering Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension 
 Clinical Study Sponsor Allergan Sales LLC 
 Trial Phase Classification Phase 3b Trial 
 Trial Indication Open-angle glaucoma or ocular hypertension 
 Trial Indication Type Treatment 
 Trial Type Efficacy 
Safety 
 Trial Length [ADDRESS_85856] Indicator No 
 Planned Minimum Age of 
Subjects 18 
 Planned Maximum Age of 
Subjects Not specified 
 Sex of Participants Both 
 Stable Disease Minimum Duration Not specified    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85857] SR   LUMIGAN 0.01% 
 Intervention Type Drug Drug 
 Pharmacological Class of Investigational Therapy Prostaglandin analog Prostaglandin analog 
 Dose Strength per Administration 10 µg 0.01% 
 Dose Units 1 implant Drop 
 Dosing Frequency Single dose Once daily in the evening 
 Route of Administration Intracameral Topi[INVESTIGATOR_78529] N/A N/A 
Trial design Study Type Interventional 
 Intervention Model 2 arm 
 Planned Number of Arms 2 
 Trial is Randomized No 
 Randomization Quotient N/A 
 Trial Blinding Schema Open-label 
 Stratification Factor N/A 
 Adaptive Design No 
 Study Stop Rules None 
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85858]-T-01-01 v3.0  10.7. Appendix 7: Contraceptive Guidan ce and Collection of Pregnancy 
Information  
Definitions: 
WOCBP 
A woman is considered fertile following mena rche and until becoming postmenopausal unless 
permanently sterile (see below). 
Women in the following cate gories are not considered WOCBP: 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
 Documented hysterectomy 
 Documented bilateral salpi[INVESTIGATOR_1656] 
 Documented bilateral oophorectomy 
Note: Documentation can come from the site  personnel’s: review of the participant’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female 
 A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormo nal contraception or HRT. However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
 Females on HRT and whose menopausal status is in doubt will be required to use one of 
the nonestrogen hormonal highly effective contraception methods or acceptable contraception methods if they wish to con tinue their HRT during the study. Otherwise, 
they must discontinue HRT to allow confir mation of postmenopausal status before study 
enrollment. 
Contraception Guidance: 
Female Participants 
WOCBP are eligible to participate if they agree to use a highly effective or acceptable method of 
contraception consistently and correctly as described in Table 10-2 . 
    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85859]-T-01-01 v3.0  Table 10-2 Highly Effective and Acceptable Contraception Methods 
Highly Effective Contraceptive Methods That Are User Dependenta  
Failure rate of < 1% per year when used consistently and correctly   
Combined (estrogen- and progestogen-c ontaining) hormonal contraception associated with inhibition of ovulation 
 Oral  
 Intravaginal  
 Transdermal  
Progestogen-only hormonal contraception associated with  inhibition of ovulation 
 Oral  
 Injectable  
Highly Effective Methods That Are User Independenta  
Implantable progestogen-only hormonal contraception associated with inhibition of ovulation 
 IUD 
 IUS 
 Etonogestrel implant (ie, Nexplanon®) 
Bilateral tubal occlusion 
Intrauterine copper contraceptive (ie, ParaGard®) 
Vasectomized Partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.   
Sexual Abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatment. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of 
the participant.   
Acceptable Methods   
Acceptable birth control methods that result in a failure of more than 1% per year include:  
 Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of 
action 
 Male or female condom with or without spermicide 
 Cap, diaphragm, or sponge with spermicide 
 Nonhormonal intrauterine device 
A combination of male condom with either cap, diaphrag m, or sponge with spermicide (double-barrier methods) 
are also considered acceptable, but not hi ghly effective, birth control methods.  
a Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for partic ipants participating in clinical 
studies.  
 
Pregnancy Testing: 
 WOCBP should only be included after a confir med menstrual period and a negative highly 
sensitive pregnancy test at Baseline. 
 Additional pregnancy testing s hould be performed at study exit,  and as required locally.    
 
 
Approval Date :  
 20-Dec-[ADDRESS_85860]-T-01-01 v3.0   Pregnancy testing will be performed whenev er a menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
 Urine pregnancy testing will be used unless the study site requires the use of serum testing, 
in which case serum testing will be used. 
Collection of Pregnancy Information: 
Female Participants Who Become Pregnant  
 The investigator will collect pregnancy information on any female participant who becomes 
pregnant while particip ating in this study. Information wi ll be recorded on  the appropriate 
form and submitted to Allergan within 24 hours of learning of a participant’s pregnancy. 
The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow up information on the participant and the neonate, and the information will be forwarded to Allergan. Generally, follow up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy 
will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
 While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
will be reported as an AE or SAE. A spontane ous or elective abortion is always considered 
to be an SAE and will be reported as such. Any poststudy pregnancy-related SAE considered reasonably related to  the study treatm ent by [CONTACT_78590] 8.3.4. W hile the investigator is not obligated to actively 
seek this information in former study particip ants, he or she may learn of an SAE through 
spontaneous reporting.  
 If a pregnancy is confirmed after the particip ant has received study treatment, the participant 
may choose to exit the study after appropriate safe ty follow up or to remain in the study for 
all safety and efficacy follow up assessments through study exit visit. 
     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85861]-T-01-01 v3.0  10.8. Appendix 8: Study Schedule Supplement  
10.8.1. Screening  
After informed consent and other documentation have been obtained , the procedures listed below 
are carried out. IOP measurements must be perf ormed in 1 day; however, other procedures (eg, 
post dilation procedures) may be performed on a different day as long as the screening 
procedures are completed within a 60-day peri od, and procedures completed on the same day 
follow the schedule as set out in the protocol. Pupil dilation/diagnostic procedures are to be 
performed after the completion of the final IOP m easurement of the day or on a different day. 
Screening procedures may be repeated for eligibility confirmation at any time prior to and during 
washout, at the discretion  of the investigator 
 Collection of demographic data 
 Collection of medical and ophthalmic history 
 Collection of AEs 
 Collection of concomitant medications and procedures 
 Collection of alcohol/caffeine/smoking consumption and sleep habits 
 Physical examination 
 Vital signs (at rest ≥ 5 minutes) 
 Collection of blood and urine samples 
The following procedures should be performed in both eyes in the order below (procedures in 
bold should be done in the order shown): 
 Pre-Hour 0 examination (perform before Hour 0 IOP): 
o Macroscopic conjunctival hyperemia assessment  
 Manifest refraction (Manifest refraction will be used to provide a correction for best 
corrected visual acuity testing. At all study visits, if there is a 2-line or more reduction in 
visual acuity from the last best-corrected vi sual acuity performed,  a repeat manifest 
refraction in both eyes and best-correct ed visual acuity will be performed.) 
 BCV A 
 IOP measurement at Hour 0  
 Anterior segment imaging (perform any time af ter Hour 0 IOP; select sites/participants 
only)     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85862]-T-01-01 v3.0   Non-contact [CONTACT_78591] : The following may be performed in any order, at any time 
before gonioscopy: 
o Visual field (If dilation is required to perform this test, then the visual field 
test should be performed after gonioscopy/angle assessment with the 
scheduled dilated exams.) 
o Specular microscopy 
o Biomicroscopy 
 Gonioscopy/angle assessment   
 Pachymetry (may be performed at any time after non-contact [CONTACT_78538]) 
 Pupil Dilation   (post dilation examinations belo w may be performed in any order) 
o Dilated ophthalmoscopy 
o Optic disc examination 
Eligibility is then determined and the IWRS is contact[INVESTIGATOR_530]. 
10.8.2. Baseline  
[IP_ADDRESS]. Office Visit 
The Baseline Office visit occurs after the washou t period has been completed. Baseline Office 
visit procedures must be performed in 1 day w ith the exception of anterior segment imaging, 
which may be performed on a different day. Pupil dilation/diagnostic pr ocedures are to be 
performed after the completion of the final Hour  0 IOP measurement. The following procedures 
are performed at the Baseline Office visit:   
 Collection of medical and ophthalmic history 
 Collection of AEs 
 Collection of concomitant medications and procedures 
 Vital signs (at rest ≥ 5 minutes) 
 Pregnancy test for WOCBP 
The following procedures should be performed in both eyes (procedures in bold should be done 
in the order shown):     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85863]-T-01-01 v3.0   Pre-Hour 0 examination (perform before Hour 0 IOP): 
o Macroscopic conjunctival hyperemia assessment  
 Manifest refraction (Manifest refraction will be used to provide a correction for best 
corrected visual acuity testing. At all study visits, if there is a 2-line or more reduction in 
visual acuity from the last best-corrected vi sual acuity performed,  a repeat manifest 
refraction in both eyes and best-correct ed visual acuity will be performed.) 
 BCV A 
 IOP measurement at Hour 0  
 Anterior segment imaging (perform any time af ter Hour 0 IOP; select sites/participants 
only) 
 Non-contact [CONTACT_78591] : The following may be performed at any time after IOP at 
Hour 0: 
o Visual field (If dilation is required to perform this test, then the visual field 
test should be performed after gonioscopy/angle assessment with the 
scheduled dilated exams.) 
o Specular microscopy 
o Biomicroscopy 
 Gonioscopy/angle assessment   
 Pachymetry (may be performed at any time after non-contact [CONTACT_78538]) 
 Pupil Dilation   (post dilation examinations belo w may be performed in any order) 
o Dilated ophthalmoscopy 
o Optic disc examination 
Eligibility is then determined and H our 0 IOP is entered into the IWRS. 
[IP_ADDRESS]. Sleep Lab Visit 
Sleep Lab visit procedures must be performed on a different day from Baseline Office visit 
procedures. The following procedures are perf ormed at the Baseline Sleep Lab visit: 
 Collection of AEs  
 Collection of concomitant medications and procedures 
 Collection of alcohol/caffeine/smoking consumption and sleep habits 
 Vital signs (at rest ≥ 5 minutes)     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85864]-T-01-01 v3.0   Perform 24-hour Sleep Lab visit on a different day from all ot her Baseline Office visit study 
procedures.     
All 24-hour Sleep Lab visit IOP exams will be performed with an Allergan-specified tonometer. 
Diurnal IOP measurements will be taken supi[INVESTIGATOR_050] ≥ [ADDRESS_85865] then sitting  ≥ [ADDRESS_85866] at 08:00 ± 30 min, 10:00 ± 30 min, 12:00 ± 30 min, 14:00 ± 30 min, 16:00 ± 30 min, 18:00 ± 30 min, 20:00 ± 30 min, and 22:00 ± 30 min.  Nocturnal IOP measurements will be taken 
supi[INVESTIGATOR_57782] ≥ [ADDRESS_85867] 00:00 ± 30 min, 02:00 ± 30 min, 04:00 ± 30min, and 06:00 ± 30 
min. Lights in individual sleep rooms will be turned off at 23:00 and nocturnal IOP 
measurements will be performed under a dim lighting with monitoring of the participant’s sleep status. Please see Procedure Manual for details. 
10.8.3. Day 1 
The following procedures are performed on Day 1: 
 Collection of AEs 
 Collection of concomitant medications and procedures 
 Vital signs (at rest ≥ 5 minutes) 
 Contact [CONTACT_78592] (this contact [CONTACT_78593] [Day 1], if needed) 
 Administer study treatment (Bimatoprost SR 10 µg) in study eye or at selected 
sites/patients, begin LUMIGAN 0.01% in the study eye 
All participants must remain in the surgical f acility for bilateral eye examination at least [ADDRESS_85868] SR administration procedure. 
Each participant will be supplied a bottle of t opi[INVESTIGATOR_78530] 3 days (including the da y of the administration) in the Bimatoprost SR 
treated eye and to follow up with the study site as per protocol. 
Participants assigned to LUMIGAN 0.01% will begi n self-administration in the study eye once 
daily in the evening (at 20:00 ± 1 hour) starti ng with the evening dose on Day 1, and will 
continue daily self-administrati on through the duration of the study.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85869]-T-01-01 v3.0  10.8.4. Day 2 Safety Visit 
The following procedures are performed on the Day 2 Safety visit: 
 Collection of AEs 
 Collection of concomitant medications and procedures 
 Vital signs (at rest ≥ 5 minutes) 
The following procedures should be performed in both eyes (procedures in bold should be done 
in the order shown): 
 Pre-Hour 0 examinations  (may perform in any order before Hour 0 IOP):  
o Macroscopic conjunctival hyperemia assessment  
 BCV A 
 IOP measurement at Hour 0  
 Non-contact [CONTACT_5148] : The following may be performed at any time after IOP at 
Hour 0:  
o Biomicroscopy 
10.8.5. Day [ADDRESS_85870] the following: 
 Collection of AEs 
 Collection of concomitant medications and procedures 
10.8.6. Week 8 Visits 
[IP_ADDRESS]. Office Visit 
Week [ADDRESS_85871] be perfor med in 1 day with the exception of anterior 
segment imaging, which may be performed on a different day. The following procedures are 
performed at the Week 8 Office visit:  
 Collection of AEs 
 Collection of concomitant medications and procedures 
 Vital signs (at rest ≥ 5 minutes)     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85872]-T-01-01 v3.0  The following procedures should be performed in both eyes (procedures in bold should be done 
in the order shown): 
 Pre-Hour 0 examinations  (may be performed in any order before Hour 0 IOP): 
o Macroscopic conjunctival hyperemia assessment  
 BCV A 
 IOP measurement at Hour 0  
 Anterior segment imaging (perform any time af ter Hour 0 IOP; select sites/participants 
only) 
 Non-contact [CONTACT_78591] : The following may be performed in any order, at any time 
before gonioscopy: 
o Biomicroscopy  
 Gonioscopy/angle assessment   
[IP_ADDRESS]. Sleep Lab Visit 
Sleep Lab visit procedures must be performed on a different day from Week 8 Office visit 
procedures. The following procedures are pe rformed at the Week 8 Sleep Lab visit: 
 Collection of AEs 
 Collection of concomitant medications and procedures 
 Collection of alcohol/caffeine/smoking consumption and sleep habits 
 Vital signs (at rest ≥ 5 minutes) 
 Perform 24-hour Sleep Lab visit on a different day from all other Week 8 Office visit 
study procedures.   
All 24-hour Sleep Lab visit IOP exams will be performed with an Allergan-specified tonometer. 
Diurnal IOP measurements will be taken supi[INVESTIGATOR_050] ≥ [ADDRESS_85873] then sitting  ≥ [ADDRESS_85874] at 8:00 ± 30 min, 10:00 ± 30 min, 12:00 ± 30 min, 14:00 ± 30 min, 16:00 ± 30 min, 18:00 ± 
30 min, 20:00 ± 30 min, and 22:00 ± 30 min. Noctur nal IOP measurements will be taken supi[INVESTIGATOR_78531] ≥ [ADDRESS_85875] 00:00 ± 30 min, 02:00 ± 30 min, 04:00 ± 30min, and 06:00 ± 30 min. 
Lights in individual sleep rooms will be turned off at 23:00 and nocturnal IOP measurements will be performed under a dim lighting with monitori ng of the participant’s sleep status. At the 
Week 8 Sleep Lab visit, partic ipants assigned to LUMIGAN 0.01% must take their evening dose 
at 20:00 ± [ADDRESS_85876] be taken not to unmask the IOP assessor. Please see Procedure 
Manual for details.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85877]-T-01-01 v3.0  10.8.7. Week 16 and Months 6, 9, and 12/Study Exit Visits 
At all visits, procedures must be performed in  1 day with the exception of anterior segment 
imaging, which may be performed on a different day at applicable visits.  The following 
procedures are performed at Week 16 and Months 6, 9, and 12/Study Exit:   
 Collection of AEs 
 Collection of concomitant medications and procedures 
 Vital signs (at rest ≥ 5 minutes) 
 Pregnancy test for WOCB P (Month 12/Study Exit only) 
The following procedures should be performed in both eyes (procedures in bold should be done in the order shown): 
 Pre-Hour 0 examination (perform before Hour 0 IOP): 
o Macroscopic conjunctival hyperemia assessment  
o BCV A 
 IOP measurement at Hour 0  
 Anterior segment imaging (perform any time af ter Hour 0 IOP; select sites/participants 
only; Months 6 and 12/Study Exit only) 
 Non-contact [CONTACT_78591] : The following may be performed in any order, at any time 
before gonioscopy: 
o Visual field (If dilation is required to perform this test, then the visual field 
test should be performed after gonioscopy/angle assessment with the 
scheduled dilated exams; M onths 6 and 12/Study Exit only) 
o Manifest refraction (Manifest refraction will be used to provide a correction 
for best corrected visual acuity testing. At  all study visits, if there is a 2-line or 
more reduction in visual acuity from the last best-corrected visual acuity performed, a repeat manifest refraction in both eyes and best-corrected visual 
acuity will be performed; Month 12/Study Exit only) 
o Specular microscopy  
o Biomicroscopy  
 Gonioscopy/angle assessment   
 Pachymetry (may be performed at any time after non-contact [CONTACT_78538])     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85878]-T-01-01 v3.0   Pupil Dilation   (post dilation examinations belo w may be performed in any order; 
Month 12/Study Exit only) 
o Dilated ophthalmoscopy 
o Optic disc examination 
IWRS is contact[CONTACT_78594] (Month 12/Study Exit 
only)     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85879]-T-01-01 v3.0  11. References 
AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship 
between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 
2000;130:429-440. 
American Academy of Ophthalmology Glaucoma Pa nel. Preferred Practice Pattern® Guidelines. 
Primary open-angle glaucoma. San Francisco,  CA: American Academy of Ophthalmology; 
2010a. 27 p. Budenz DL. A clinician's guide to the assessment and management  of nonadherence in glaucoma. 
Ophthalmology. 2009;116:S43-S47. Cohen JS, Gross RL, Cheetham JK, VanDenbur gh AM, Bernstein P, Whitcup SM. Two-year 
double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular 
hypertension. Surv Ophthalmol. 2004;49 (Suppl 1):S45-S52. 
Cook C, Foster P. Epi[INVESTIGATOR_78532]: What’s new? Can J Ophthalmol. 2012;47:223-226. European Glaucoma Society (EUGS). Terminology and Guidelines for Glaucoma. 4th ed. 
PubliComm: Italy; 2014. 187p.  
Francis BA, Ianchulev T, Schofield JK, Minckl er DS. Selective laser trabeculoplasty as a 
replacement for medical therapy in op en-angle glaucoma. Am J Ophthalmol. 
2005;140(3):524-525. Friedman DS. Introduction: new insights on e nhancing adherence to topi[INVESTIGATOR_78533]. Ophthalmology. 2009;116:S29. 
Garg A, Gazzard G. Selective laser trabeculopl asty: past, present, and future. Eye (Lond). 
2018;32(5):863-876. 
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengt sson B, Hussein M. Reduction of intraocular 
pressure and glaucoma progressi on: results from the early manifest glaucoma trial. Arch 
Ophthalmol. 2002;120:1268-1279. Higginbotham EJ, Schuman JS, Goldberg I, Gr oss RL, VanDenburgh AM, Chen K, et al. 
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular 
hypertension. Arch Ophthalmol. 2002;120:1286-1293. 
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Ke ltner JL, Miller JP, et al. The Ocular 
Hypertension Treatment Study: a randomized tria l determines that topi[INVESTIGATOR_78534]-angle glaucoma. Arch Ophthalmol. 
2002;120(6):701-713; discussion 829-830. 
Konstas AG, Quaranta L, Mikropoulos DG, et al. Peak intraocular pressure and glaucomatous 
progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012;28(1):26-32. 
Koucheki B, Hashemi H. Selectiv e laser trabeculoplasty in the tr eatment of open-angle glaucoma. 
J Glaucoma. 2012;21(1):65-70.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85880]-T-01-01 v3.0  Kozak KR, Crews BC, Morrow JD, Wang L-H, Ma YH,  Weinander R, et al. Metabolism of the 
endocannabinoids, 2-arachidonylgly cerol and anandamide, into pr ostaglandin, thromboxane, and 
prostacyclin glycerol esters and et hanolamides. J Biol Chem. 2002;277:[ZIP_CODE]-[ZIP_CODE]. 
Kramer TR, Noecker RJ. Comparison of the morphologic changes af ter selective laser 
trabeculoplasty and argon laser trabeculoplas ty in human eye bank eyes. Ophthalmology. 
2001;108(4):773-9. 
Krauss AH, Woodward DF. Update on the mechanis m of action of bimatoprost: a review and 
discussion of new evidence. Surv Ophthalmol. 2004;49(Suppl 1):S5-S11. 
Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical 
outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surg ery. Ophthalmology. 2001;108:1943-1953. 
Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour  pattern of intraocular pressure in the aging 
population. Invest Ophthalmol Vis Sci. 1999;40(12):2912-7. 
Liu JH, Sit AJ, Weinreb RN. Variation of 24-hour intraocular pressure in  healthy individuals: 
right eye versus left eye. Ophthalmology. 2005;112(10):1670-5. 
LUMIGAN 0.01% [package insert]. Irvine, VA: Allergan; 2017. 
Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F, et al. Prostaglandin 
ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther. 
2004;309:745-757. 
Mosaed S, Dustin L, Minckler DS. Comparativ e outcomes between newer and older surgeries for 
glaucoma. Trans Am Ophthalmol Soc. 2009;107:127-133; discussion 134-135. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular 
hypotensive treatment in patients with glaucoma  or ocular hypertension an evidence-based 
review. Ophthalmology. 2005;112(6):953-961. 
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br 
J Ophthalmol. 2006;90(3):262-267. 
Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors for the development 
of glaucomatous visual field loss in ocular  hypertension. Arch Ophthalmol. 1994;112:644-649. 
Realini T. Selective laser trabeculoplasty: a review. J Glaucoma. 2008;17(6):497-502. 
Skuta GL, Cantor LB, and Weiss JS, eds. Basi c and clinical science course. In: Glaucoma 
(Section 10, 2008-2009). San Francisco, Californi a: American Academy of Ophthalmology; 
2008:1-17. 
Stamper RL, Lieberman MF, Drake MV. Introducti on and classification of the glaucomas. In: 
Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. 8th ed. Amsterdam: Mosby [CONTACT_54469]; 
2009. p. 1-7.  
Tsai JC. A comprehensive perspective on patient adherence to topi[INVESTIGATOR_78535]. 
Ophthalmology. 2009;116:S30-S36.     
 
 
Approval Date :  
 20-Dec-[ADDRESS_85881]-T-01-01 v3.0  Varma R, Lee PP, Goldberg I, Kotak S. An a ssessment of the health and economic burdens of 
glaucoma. Am J Ophthalmol. 2011;152:515-522. 
Weber A, Ni J, Ling KH, Acheampong A, Tang-Liu DD, Burk R, et al. Formation of 
prostamides from anandamide in FAAH knockout  mice analyzed by [CONTACT_78595]. J Lipid Res. 2004;45:757-763. 
Williams RD, Cohen JS, Gross RL, Liu CC, Safy an E, Batoosingh AL. Long-term efficacy and 
safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: 
year 4. Br J Ophthalmol. 2008;92:1387-1392. Woodward DF, Chan MF, Burke JA, Cheng-Bennett A,  Chen G, Fairbairn CE, et al. Studies on 
the ocular hypotensive effects of prostaglandi n F2 alpha ester prodrugs and receptor selective 
prostaglandin analogs. J Ocul Pharmacol. 1994;10:177-193. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM. The pharmacology of 
bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S337-S345. 
Woodward DF, Phelps RL, Krauss AH, Weber A, S hort B, Chen J, et al. Bimatoprost: A novel 
antiglaucoma agent. Cardiovasc Drug Rev. 2004;22:103-120. Yu M, Ives D, Ramesha CS. Synthesis of pros taglandin E2 ethanolamide from anandamide by 
[CONTACT_78596]-2. J Biol Chem. 1997;272:[ZIP_CODE]-[ZIP_CODE].     